



1/PW

PATENT
00833-P0043A SPM

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	Timothy Raymond Hirst
Application No. 10/743,391	Filing Date: December 22, 2003
Title of Application:	Mutant Forms Of EtxB and CtxB And Their Use As Carriers
Confirmation No. 7178	Art Unit: 1632
Examiner	

Commissioner for Patents
Post Office Box 1450
Alexandria, VA 22313-1450


Submission of Priority Document

Dear Sir:

Applicant hereby submits a certified copy of the priority document, Great Britain Application No. 0115382.4, to perfect Applicant's claim of priority.

Respectfully submitted,


April 19, 2007



Stephen P. McNamara, Registration No. 32,745
Attorney for Applicant
ST.ONGE STEWARD JOHNSTON & REENS LLC
986 Bedford Street
Stamford, CT 06905-5619
203 324-6155

Mailing Certificate: I hereby certify that this correspondence is today being deposited with the U.S. Postal Service as *First Class Mail* in an envelope addressed to:
Commissioner for Patents and Trademarks; Post Office Box 1450; Alexandria, VA
22313-1450.

April 19, 2007



Alice Jones




The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ


I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Re-regulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1985 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.


In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed 
Dated 7 March 2007



1/77



The Patent Office

Cardiff Road
Newport
South Wales
NP10 8QQ**Request for a grant of a patent**

(See the notes on the back of this form you can also get an explanatory leaflet from the Patent Office to help you fill in this form)

1. Your reference

P011729GB CTH

25JUN01 E639693-19 002246
P01/7700 0.00-0115382.42. Patent application number
(The Patent Office will fill in this part)**0115382.4**

22 JUN 2001

3. Full name, address and postcode of the
or of each applicant
(underline all surnames)University of Bristol
Senate House
Tyndall Avenue
Bristol BS8 1TH
United Kingdom Patents ADP number (if you know it)If the applicant is a corporate body, give
the country/state of its incorporation

United Kingdom

758105

4. Title of the invention

Mutant

5. Name of your agent (if you have one)

D Young & Co

"Address for service" in the United Kingdom
to which all correspondence should be sent
(including the postcode)21 New Fetter Lane
London
EC4A 1DA

Patents ADP number (if you know it)

59006

6. If you are declaring priority from
one or more earlier patent
applications, give the country and
date of filing of the or each of these
earlier applications and (if you know
it) the or each application number

Country

Priority application
number
(if you know it)Date of filing
(day/month/year)

1st

2nd

3rd

7. If this application is divided or otherwise
derived from an earlier UK application,
give the number and filing date of the
earlier applicationNumber of earlier
applicationDate of filing
(day/month/year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:
 () a) any applicant named in part 3 is not an inventor, or
 b) there is an inventor who is not named as an applicant, or
 c) any named applicant is a corporate body.
 See note (d))

Yes

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document	Continuation sheets of this form	0
	Description	64
	Claim(s)	3
	Abstract	1
	Drawing(s)	11

10. If you are also filing any of the following, state how many against each item	Priority Documents	No
	Translations of Priority Documents	No
	Statement of inventorship and right to grant of a patent (Patents Form 7/77)	No
	Request for preliminary examination and search (Patents Form 9/77)	No
	Request for substantive examination (Patents Form 10/77)	No
	Any other documents (Please specify)	No

11. I/We request the grant of a Patent on the basis of this application.

Signature

Date


D YOUNG & CO
 Agents for the Applicants

22 Jun 2001

12. Name and daytime telephone number of person to contact in the United Kingdom Charles Harding 023 8071 9500

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- d) If you answered 'Yes' Patents Form 7/77 will need to be filed.
- e) Once you have filled in the form you must remember to sign and date it.
- f) For details of the fee and ways to pay please contact the Patent Office.

1

MUTANT

FIELD OF THE INVENTION

5

The present invention relates to improved delivery/targeting vehicles.

More in particular, the present invention relates to the use of mutant forms of EtxB, or CtxB as vehicles to deliver and/or target an agent to a target site.

10

In particular, the present invention relates to the use of mutant forms of EtxB or CtxB as vehicles to deliver an agent to a target site for the treatment of a disease or condition in a subject in need of the same.

15

BACKGROUND OF THE INVENTION

EtxB and CtxB as carrier molecules for the A subunit

Escherichia coli (*E. coli*) heat labile enterotoxin (Etx) and its closely related homologue, cholera toxin (Ctx) from *Vibrio cholerae*, are examples of protein toxins which bind to glycolipid receptors on host cell surfaces. Each toxin consists of six noncovalently linked polypeptide chains, including a single A subunit (27 kDa) and five identical B subunits (11.6 kDa) which bind to GM-1 ganglioside receptors found on the surfaces of mammalian cells (Nashar *et al* 1996 Proc Natl Acad Sci 93: 226-230). The A subunit is responsible for toxicity possessing adenosine diphosphate (ADP) ADP-ribosyltransferase activity, whereas the B subunits (EtxB and CtxB) are non-toxic oligomers which bind and cross-link a ubiquitous cell surface glycolipid ganglioside, called GM-1, thus facilitating A subunit entry into the cell.

30 *B subunit is a potent immunogen*

In contrast to the poor immunogenicity of the A subunit alone, both EtxB and CtxB are exceptionally potent immunogens and their respective holotoxins, Etx and Ctx (which comprise the A and B subunits) are known to be potent adjuvants when given

orally in combination with unrelated antigens (Ruedl *et al* 1996 *Vaccine* 14: 792-798; Nashar *et al* 1993 *Vaccine* 11: 235; Nashar and Hirst 1995 *Vaccine* 13: 803; Elson and Ealding 1984 *J Immunol* 133: 2892; Lycke and Holmgren 1986 *Immunology* 59: 301). Because of their immunogenicity, both EtxB and CtxB have been used as carriers for other epitopes and antigens (Nashar *et al* 1993 *ibid*) and have been used as components of vaccines against cholera and *E.coli* mediated diarrhoeal diseases (Jetborn *et al* 1992 *Vaccine* 10: 130).

B subunit is a potent immunomodulator

We have demonstrated the surprising finding that the EtxB subunit is also capable of acting as an immunomodulator in immune disorders. In this respect, we have disclosed in WO 97/02045 that EtxB binds to GM-1 ganglioside receptors which are found on the surfaces of mammalian cells and that this binding induces differential effects on lymphocyte populations including a specific depletion of CD8+ T cells and an associated activation of B cells.

One of the most unexpected and striking effects of the B-subunits is their capacity to trigger the selective apoptosis of CD8+ T-cells, as well as to alter CD4+ T-cell differentiation, activate B-cells and modulate antigen processing and presentation by macrophages (Williams, N. A., Hirst, T. R. & Nashar, T. O. (1999) *Immunol. Today* 20, 95-101.). These potent immunological properties have led to testing of the B-subunits as adjuvants for stimulating mucosal and systemic responses to co-administered antigens (Verweij, W. R., de Haan, L., Holtrop, M., Agsteribbe, E., Brands, R., van Scharrenburg, G. J. M. & Wilschut, J. (1998) *Vaccine* 16, 2069-2076. Richards, C. M., Aman, A. T., Hirst, T. R., Hill, T. J. & Williams, N. A. (2001) *Journal of Virology* 75, 1664-1671.); and as agents for down-regulating proinflammatory autoimmune diseases such as rheumatoid arthritis and diabetes (Williams, N. A., Stasiuk, L. M., Nashar, T. O., Richards, C. M., Lang, A. K., Day, M. J. & Hirst, T. R. (1997) *Proc. Natl. Acad. Sci. (USA)* 94, 5290-5295).

Mutant B sub-units – No GM-1 binding – no immunomodulation

These effects are absent when a mutant EtxB protein (G33D) (lacking GM-1 binding activity) is employed. Consequently, these experimental results suggested that all of
5 the functionalities associated with EtxB and CtxB are attributable to the capacity of the EtxB and CtxB subunits to bind to the GM-1 receptor and that immunomodulation and other effects of Etx and Ctx are mediated through GM-1 binding since mutants lacking the capacity to bind GM-1 (such as EtxB (G33D)) fail to act as adjuvants or immunomodulators.

10

It is well known that CtxB and EtxB contain an extensive conserved segment spanning residues 45 to 74 that contains an exposed loop from Val-52 (V52) to Ile-58 (I58) located on the lower convoluted surface of the molecule (Hirst, T. R. (1999) in
15 *The Comprehensive Sourcebook of Bacterial Protein Toxins*, ed. Freer, J. E. A. a. J. H. (Academic Press, London), pp. 104-129). This loop is normally oriented towards the cell membrane and forms part of the GM1-binding surface, with residues Gln-56, His-57 and Ile-58 involved in a network of solvent-mediated hydrogen bonds that is conserved in the presence of bound GM1-pentasaccharide (Merritt, E. A., Sixma, T.
20 Kalk, K. H., Van Zanten, B. A. M. & Hol, W. G. J. (1994) Mol. Microbiol. 13, 745-753.).

Mutant B sub-units – GM-1 binding – no immunomodulation

We have demonstrated in WO 00/14114 that CtxB molecules with point mutations at
25 three separate sites within the β 4- α 2 loop (positions 51, 56 and 57) retained GM-1 binding activity, but lacked other activities, such as toxicity and the capacity to upregulate CD25 and trigger apoptosis of CD8-positive T-cells. We have also shown that EtxB molecules with point mutations in position H57 of EtxB showed a similar loss in triggering /modulation of immune cell populations. In addition, Ctx holotoxins comprising B subunits with mutations also showed a defect in an ability to trigger electrogenic chloride secretion, the primary secretory event responsible for mediating diarrhoea. These findings clearly demonstrated that CtxB and EtxB molecules with point mutations within the β 4- α 2 loop were capable of binding to the GM-1 receptor but were lacking in an immunomodulatory effect which suggested that not all of the

effects of Etx and Ctx and in particular, the immunomodulatory effects, were mediated through but not exclusively by GM-1 binding.

In particular, WO 00/14114 confirmed the importance of the B-subunit E51-I58 loop,
5 and in particular H57 in mediating the immunomodulatory properties of the molecule.
The teachings in WO 00/14114 demonstrated that the β 4- α 2 loop of EtxB/CtxB is
responsible for a secondary binding activity and so the use of this loop in isolation
from the rest of the EtxB/CtxB molecule (for example as a peptide), may permit the
secondary binding activity to occur in the absence of the first. Thus, the selective
10 mutation of the β 4- α 2 loop, or a peptide derived from this loop, may be exploited
with a view to increasing the affinity of the secondary binding activity. By increasing
the affinity of the secondary binding activity, the interaction with GM-1 may be
further obviated. In summary, the teachings in WO 00/14114 demonstrated that the
"secondary" binding activity of an isolated "loop" peptide is not necessarily dependent
15 on a primary GM-1 binding event as is found with full length CtxB and EtxB to mediate
the immunomodulatory response.

Thus, it is clear from the above studies that the wild type B subunit is a potent
immunogen and a potent immunomodulator whereas the mutations in the B subunit
20 can result in either no GM-1 binding and no immunomodulation or the retention of
GM-1 binding but with no immunomodulatory capability.

The immunological mechanisms underlying the use of the B-subunit.

25 The B-subunits ability to modulate the immune response is dependent on its capacity
to modulate the activity of T-cells, B-cells and populations of antigen presenting cells.
Each of these cell types plays a critical role in the development of the immune
response. In the normal response to a foreign organism, antigens are internalised by
antigen presenting cells, of which professional antigen presenting cells, such as
30 dendritic cells are the most important. These cells are specialised in breaking down
proteins into short amino acid sequences (peptides) which associate with major
histocompatibility complex (MHC) molecules which are then transported to the cell
surface. Foreign peptides bound to class II MHC molecules are recognised by T-

helper cells (CD4+ T-cells) which are activated as a result and begin to divide, differentiate and secrete hormone-like messengers called cytokines. The T-helper cells then co-ordinate and maintain the immune response.

5 Subsequent responses can involve the activation of i) B-cells which mature into plasma cells capable of producing antibodies, ii) macrophages and neutrophils which enter the sites of infection and ingest foreign material leading to its destruction, and iii) other types of T-cell (CD8+ T-cells) which can recognise virally infected cells of the body and kill them. Most normal immune responses will involve activation of all
10 of these components to some extent. However, it is clear that certain factors can affect which particular components are dominant.

In addition, in certain circumstances it is clearly beneficial to be able to tailor which type of response is elicited. By way of example, it is well known that cytotoxic T
15 lymphocytes (CTLs) play a central role in immune surveillance by recognising foreign antigenic peptides bound to MHC class I molecules and killing virally infected and potentially cancerous cells. Thus, it would be beneficial to tailor the immune response in the direction of the cytotoxic T-cell responses in order to facilitate the removal of infectious agents which reside within cells of the body, such
20 as viruses and certain bacteria.

The effective induction of cytotoxic T-cell responses requires the entry of antigens into the cytosol of antigen presenting cells where they can enter the endogenous class I processing and presentation pathway. However, current immunisation strategies,
25 using peptide or protein antigens, generally fail to elicit a CTL response since these antigens are unable to or are able to only partially access the intracellular compartments where loading of class I molecules occurs. Thus, an efficient delivery system which results in the targeting of antigens into the cytosol is required.

30 It is known that either wild type EtxB or CtxB may be used as vehicles for the delivery of attached peptides into cells such as MHC Class I bearing cells or professional APCs to achieve the presentation of the such antigenic determinants by MHC class I molecules. The teachings in WO 99/58145 also indicate that the wild

type EtxB or CtxB free from of whole toxin, may be used in a conjugate with a peptide or an antigenic determinant to target their delivery to a cell.

One potential disadvantage associated with the use of wild type EtxB or Ctx B is that
5 the potent immune responses engendered to these molecules may preclude their repeated use as drug carrier vehicles. Thus, it is desirable to find new ways for delivering an agent to an intracellular compartment of a target cell without triggering a potent immunomodulatory response or a potent immune response such as that induced by wild type CtxB or EtxB molecules.

10

SUMMARY OF THE INVENTION

The present invention now provides the use of a mutant form of EtxB or CtxB to deliver an agent to a target cell wherein the mutant has GM-1 binding activity; but
15 wherein the mutant has a reduced immunogenic and immunomodulatory activity relative to the wild type form of EtxB or CtxB.

DETAILED ASPECTS OF THE INVENTION

20 Other aspects of the present invention are presented in the accompanying claims and in the following description and discussion. These aspects are presented under separate section headings. However, it is to be understood that the teachings under each section heading are not necessarily limited to that particular section heading.

25 SURPRISING/UNEXPECTED FINDINGS

We have now found mutant forms of CtxB and EtxB which bind GM-1 receptors that are capable of acting as delivery vehicles but which do not trigger either a potent immunomodulatory or a potent anti-carrier immune response (that is, a potent
30 immunogenic response). The mutant forms/derivatives of CtxB and EtxB of the present invention can bind GM-1 and enter mammalian cells, even though they have a reduced immunogenicity and a reduced immunomodulation capability.

Although workers in the field knew that the GM-1 receptor acts as a functional receptor for Ctx/CtxB and Etx/EtxB, there was no disclosure or suggestion in the prior art of the possibility that mutant forms of CtxB or EtxB which bind to GM-1 but which do not have any potent immunogenic or immunomodulatory effect – could be used as vehicles for delivering agents into mammalian cells without inducing any possible undesirable side effects which could preclude repeated use of the carrier moiety.

ADVANTAGES OF THE INVENTION

The present invention is advantageous because the ability of the mutant forms of CtxB and EtxB to enter mammalian cells without inducing a potent anti-B-subunit response and immunomodulatory response means that the mutants are better drug or peptide delivery vehicles for agents, such as drugs or antigenic peptides, than the corresponding wild-type EtxB or CtxB molecules.

The present invention is also advantageous because the mutant of the present invention, which has an effect on vesicular internalisation mediated by GM1-binding may be linked, by for example, conjugation with an agent, such as an antigen or an antigenic determinant, to upregulate the presentation of the antigen or the antigenic determinant, or the antigenic determinant derived from said antigen, by MHC class I molecules to stimulate CTL responses.

The delivery of agents, such as antigens or antigenic determinants, is advantageous because the delivery allows the presentation of agents, such as antigens or antigenic determinants on MHC class 1 molecules, which can lead to the induction of class I restricted T-cell responses. As indicated above, such responses are beneficial in affording protection against diseases and conditions such as viral infections and cancers.

The delivery of agents, such as pro-drugs, using the mutant forms of CtxB and EtxB is especially advantageous if the prodrug is activated by entry into acidic endosomes.

In addition, the present invention is advantageous because the mutant forms of CtxB or EtxB or VtxB may be manipulated to selectively deliver one or more agents to the cytosol and/or the nucleus of a mammalian target cell.

5 Other advantages are discussed and are made apparent by the following commentary.

DETAILED DESCRIPTION

CTX/CTXB

10 As used herein, the term "Ctx" refers to the cholera toxin and "CtxB" to the B subunit of the cholera toxin. In other texts, these may sometimes be identified as "CT" or "Ct" and "CTB" or "CtB" respectively.

ETX/ETXB

The term "Etx" herein means the *E. coli* heat labile enterotoxin, and "EtxB" is the B subunit of Etx. In other texts, these may sometimes be identified as "LT" or "Lt" and "LTB" or "LtB" respectively.

WILD TYPE CtxB and EtxB

As used herein the term "wild type CtxB or EtxB" refers to a CtxB or EtxB molecule with an activity which is substantially the same as the native CtxB or EtxB molecules.

25 That is, the term includes molecules which retain the capacity to bind GM1 and/or the capacity to mimick the effects of binding to GM1 and which retain the immunomodulatory capability of these B subunits.

MUTANT FORMS OF CtxB and EtxB

30 As used herein, the term "mutant form of CtxB and EtxB" refers to a CtxB or EtxB subunits and variants or derivatives thereof as well as variants and/or derivatives of the nucleotide sequence coding for these protein molecules which retain the capacity to bind GM1 and/or the capacity to mimick the effects of binding to GM1 but which do

not retain the potent immunogenic and immunomodulatory properties observed with the wild type EtxB or CtxB subunits or which have substantially reduced immunogenic and immunomodulatory activity relative to the wild type EtxB or CtxB subunits. A mutant form of CtxB or EtxB may arise naturally, or may be created artificially (for example by site-directed mutagenesis or by additions, substitutions or deletions in the sequences comprising or encoding the mutant forms of CtxB or EtxB. By way of example, a mutant form of CtxB or EtxB may result from mutation in the β 4- α 2 loop of CtxB or EtxB.

10 Preferably the mutation is in the region spanning amino acid residues E51-I58 of the β 4- α 2 loop of CtxB or EtxB.

Preferably the mutation is at amino acid residues 51, 56 and/or 57 of the β 4- α 2 loop of CtxB or EtxB.

15 Preferably the mutation is a point mutation in the His57 amino acid. Preferably the mutation is an alanine (A) or a serine (S) amino acid (hereinafter referred to as either a H57A or H57S mutation).

20 The terms "variant" or "derivative" in relation to the mutant EtxB or CtxB subunits of the present invention includes any substitution of, variation of, modification of, replacement of, deletion of or addition of one (or more) amino acids from or to the amino acid sequence comprising the wild type EtxB or CtxB molecule or any substitution of, variation or modification of the nucleotide sequence encoding the wild type EtxB or CtxB subunits providing the resultant entity retains a GM-1 binding activity but does not retain the same and/or similar potent immunogenic and immunomodulatory properties as the wild type CtxB or Etx subunits or which has substantially reduced immunogenic and immunomodulatory activity relative to the wild type EtxB or CtxB subunits. The variant or derivative need not be derived from the wild type EtxB or CtxB. By way of example, the variant or derivative may be expressed and/or synthesised from or by using suitable starting products so that the final product mimics the activity of the mutant form of CtxB and/or EtxB.

The term "mutant form of CtxB and EtxB" may be referred to interchangeably as the "mutant form" of the B subunit throughout the text or just the "mutant" of the present invention.

5 For the avoidance of doubt, the term "mutant form of CtxB and EtxB" does not include the wild type form of CtxB and EtxB.

PREPARATION OF MUTANT FORMS OF CtxB and EtxB.

10 The mutant forms of CtxB and EtxB as used herein include natural forms of the molecule which have been isolated and recombinant and/or synthetic forms of the molecules.

Preferably the mutant forms of CtxB and EtxB are prepared using recombinant means.

15 The recombinant mutant forms of CtxB and EtxB may be produced by a method in which the gene or genes coding for the specific polypeptide chain (or chains) from which the mutant B subunit is formed, is inserted into a suitable vector and then used to transfect a suitable host. For example, the gene coding for the polypeptide chain of
20 the EtxB subunit may be inserted into, for example, a plasmid vector pMMB66EH to generate pMMB68 which is then used to transfect host cells, such as *Vibrio sp.60*. The protein is purified and isolated in a manner known *per se*. Mutant genes expressing active mutant CtxB and EtxB subunits may be produced by known methods from the wild type genes CtxB and EtxB subunits.

25 Preferably, the mutant forms of CtxB and EtxB are substantially isolated and/or substantially pure and/or substantially free of toxin.

As used herein, the terms "isolated" and "purified" refer to molecules, either nucleic
30 or amino acid sequences, that are removed from their natural environment and/or isolated or separated from at least one other component with which they are naturally associated. A protein may be mixed with carriers or diluents which will not interfere with the intended purpose of the substance and still be regarded as substantially isolated.

GM-1 GANGLIOSIDE RECEPTOR (GM-1 or GM1)

The GM1 ganglioside receptor is a member of family of gangliosides comprising sialic acid containing glycolipids (also called glycosphingolipids) which are formed by a hydrophobic portion, the ceramide, and a hydrophilic part, that is the oligosaccharide chain. Gangliosides are defined as any ceramide oligosaccharide carrying, in addition to other sugar residues, one or more sialic residues (Oxford Dictionary of biochemistry and molecular biology. Oxford University Press. 1997. Eds Smith AD, Datta SP, Howard Smith G, Campbell PN, Bentley R and McKenzie HA). Although first described in neural tissue, several studies have shown that gangliosides are almost ubiquitous molecules expressed in all vertebrate tissues. Within cells, gangliosides are usually associated with plasma membranes, where they may act as receptors for a variety of molecules and take part in cell-to-cell interaction and in signal transduction. In addition, gangliosides are expressed in cytosol membranes like those of secretory granules of some endocrine cells such as the pancreatic islets and adrenal medulla.

Gangliosides contain in their oligosaccharide head groups one or more residues of a sialic acid which gives the polar head of the gangliosides a net negative charge at pH 20 7.0. The sialic acid usually found in human gangliosides is N-acetylneuraminic acid. Over 20 different types of gangliosides have been identified, differing in the number and relative positions of the hexose and sialic residues which form the basis of their classification. Nearly all of the known gangliosides have a glucose residue in glycosidic linkage with ceramide, residues of D-galactose and N-acetyl-D-galactosamine are also present.

In the ganglioside nomenclature of gangliosides, devised by Svennerholm (Biochemistry Lehninger 2nd Ed 1975 Worth Publishers Inc p 294-295) the subscript letters indicate the number of sialic groups. M is monosialo, D is disialo and T is trisialo.

One of the best studied members of the ganglioside family is the monosialosylganglioside, GM1, which has been shown to be the natural receptor for

the cholera toxin. Soluble ganglioside GM1 binds to the toxin with high affinity and inactivates it (Svennerholm 1976 *Adv Exp Med Biol* 71: 191-204).

The chemical formula for GM1 can be represented as:

5



where Glc is D-glucose, Gal is D-galactose, GalNAc is N-acetyl-D-galactosamine; NeuAc is N-acetylneuraminic acid, Cer is ceramide.


10

The chemical formula for GM1 can also be represented as



15

or



20 The x-ray crystal structures of Etx bound to lactose (Sixma *et al* 1992 *Nature* (London) 355: 561-564) and CtxB bound to the pentasaccharide of GM1 (Merritt *et al* 1994 *Protein Sci* 3: 166-175) have revealed that CtxB and EtxB bind to the terminal galactose and sialic acid moieties of GM1 and that such binding does not induce any striking changes in B subunit conformation.

25 GM-1 BINDING ACTIVITY

The term "GM1 binding activity" refers to an entity such as a CtxB or EtxB subunit or a mutant form thereof which is capable of interacting with a GM1 ganglioside receptor.

30

An assay for determining GM-1 binding activity would be readily determinable to those skilled in the art. For example, the assay may utilise GM-1 bound to a solid support and wherein the substance is then passed across the bound GM-1. Non-

elution of the mutant form is indicative that it does bind to GM-1. In a more preferred aspect, the assay is that described in WO 97/02045.

IMMUNOGENIC

5

As used herein, the term "immunogenic" means an anti - B subunit response (also referred to as an anti-carrier response). The term "immunogenic" does not mean a response against any antigen associated with the B subunit and/or any antigen which the B subunit might carry.

10

IMMUNOMODULATOR

The term "immunomodulator" or "immunomodulatory molecule" or "immunomodulatory factor(s)" refer to molecules or factors that, when made by one or more cells involved in an immune or inflammatory response, or which when added exogenously to the cells, causes the immune or inflammatory response to be different in quality or potency from that which would have occurred in the absence of the factor.

An immunomodulator may modulate the immune response by altering, for example, the specific reactivity or the nonspecific effector associated mechanisms of the host.

By way of example, an immunomodulator may trigger cell-signalling events or induce potent anti-B-subunit immune responses or be capable of inducing, for example, a differential effect on cells, such as lymphocyte cells - preferably leading to induction of apoptosis in CD8+ T cells and/or enhanced activation of CD4+ cells and/or the polyclonal activation of B cells and/or a modulation in the expression and/or levels of immunostimulatory molecules such as cytokines, lymphokines and/or immune co-factors. The term "differential effect on leukocyte cells" may include but is not limited to a specific depletion of CD8+ cells (through for example apoptosis), the enhanced activation of CD4+ T cells (T helper cells (Th)) and/or an associated activation of B cells. The immunomodulator may also be capable of downregulating the pathological response of Th1 and/or Th2-associated immune responses and upregulating the production of antibodies at mucosal surfaces.

IMMUNOMODULATION

The immunomodulatory effects observed with wild type EtxB or CtxB may be GM-1 mediated intracellular signalling effect which may be triggered by GM-1 binding.

5 Without being bound by theory, the binding of the B-subunits to receptors such as GM1 triggers signal transduction and induce toxin internalisation. The pentameric cross-linking of the GM1 receptor causes local alterations in membrane dynamics and the microlipid environment, which in turn influences the activity of integral membrane proteins that participate in cell-signalling or alternatively may permit direct

10 or indirect interaction of bound CtxB or EtxB molecules with membrane associated molecules responsible for triggering signalling that result in immunomodulation.

IMMUNOMODULATION ASSAY

15 An assay for determining whether a mutant form of EtxB or CtxB has immunomodulatory properties would be readily determinable to those skilled in the art. For example, the assay may measure and/or determine an effect on cell populations, such as lymphocyte cell populations. These effects can include but are not limited to an induction of apoptosis in CD8+ T cells, the enhanced activation of

20 CD4+ T cells (Th cells) and the polyclonal activation of B cells. In addition, or in the alternative, the assay could be based on determining and/or measuring particular cell surface marker(s) indicative of activation of certain intracellular events (e.g. measuring an increase in CD25 expression). The quality or potency of a response may be measured by a variety of other assays known to one skilled in the art. These

25 assays may include but are not limited to *in vivo* studies such as whole animal studies for immunogenic and/or immunomodulatory responses or *in vitro* studies for measuring same.

AGENT

30

The mutant forms of CtxB or EtxB of the present invention may be used to deliver an agent to a target mammalian cell. As used herein, the term "agent" can include but is not limited to a peptide of interest or a protein sequence of interest (POI), an antigen, an antigenic determinant, an antibody and a nucleotide sequence of interest (NOI).

The term "agent" can include one or more agents. By way of example, the mutant of the present invention may be used to delivery one or more POI(s), one or more antigen(s) and/or one or more antigenic determinant(s) and/or one more NOI(s) to a target mammalian cell. The agent can be a therapeutic and/or a diagnostic agent.

5

ANTIGEN

Preferably the antigen is derivable from a tumour associated antigen (TAA).

10

TAA

The term "tumour associated antigen (TAA)" is used herein to refer to any TAA or antigenic peptide thereof. The antigen being one that is expressed by the tumour itself or cells associated with the tumour such as parenchymal cells or those of the 15 associated vasculature. The term "tumour associated antigen (TAA)" includes antigens that distinguish the tumour cells from their normal cellular counterparts where they may be present in trace amounts.

20

Alternatively, the antigen also be derived from pathogenic agents derived from tumour cells which multiply unrestrictedly in an organism and may thus lead to pathological growths. Examples of such pathogenic agents are described in Davis, B.D. *et al* (Microbiology, 3rd ed., Harper International Edition). These antigens may include tumour associated antigens (TAA) which can serve as targets for the host immune system and elicit responses which result in tumour destruction. Examples of 25 such antigens include but are not limited to MART-1 (Melanoma Antigen Recognised by T cells-1) MAGE-1, MAGE-3, 5T4, gp100, Carcinoembryonic antigen (CEA), prostate-specific antigen (PSA), MUCIN (MUC-1), tyrosinase.

INFECTIOUS AGENT

30

Preferably the antigen is derivable from an infectious agent.

Preferably the antigen is derivable from a viral antigen.

In one embodiment of the present invention, the antigen may be derived from pathogenic viruses. These include but are not limited to Human Immunodeficiency Virus (HIV) (GP-120, p17, GP-160 antigens), influenza (NP, HA antigen), herpes simplex (HSVdD antigen), human papilloma virus, equine encephalitis virus, hepatitis 5 (Hep B Surface Antigen), feline leukaemia virus, canine distemper, rabies virus, epstein barr virus (EBV), influenza virus.

In another embodiment of the present invention, the antigenic determinant may be derived from pathogenic bacteria which include but are not limited to Chlamydia, 10 Mycobacteria, Plasmodium Falciparum, and Legionella. Pathogenic protozoans include but are not limited to malaria, Babesia, Schistosoma, Toxoplasma and Toxocara canis. Pathogenic yeast include Aspergillus and invasive Candida. In a preferred embodiment the pathogenic microorganism is an intracellular organism.

15 If the infectious agent is selected from the group consisting of enteropathogenic, enterotoxigenic, enteroinvasive, enterohaemorrhagic and enteroaggregative *E.coli*, then the antigenic determinant may be an antigenic determinant of a bacterial toxin or adhesion factor.

20 ISOLATION OF AN ANTIGEN OF INTEREST

There are a number of known methods by which it is possible to isolate an antigen of interest. For example, an antigenic agent comprising one or more potential protective 25 antigens may be extracted from the agent, or from cells infected by the agent, by use of procedures that allow the recovery of the antigens. This may include the use of cell disruption techniques to lyse cells such as sonication and/or detergent extraction. Centrifugation, ultrafiltration or precipitation may be used on collected antigen preparations. The antigen preparation containing HSV-1 glycoproteins described in Richards et al., (1998) J. Infect. Dis. 177;1451-7, exemplifies such a method.

30 Also, antigens of an antigenic agent, or from cells infected by a said agent may be extracted by a variety of procedures, including but not limited to, urea extraction, alkali or acid extraction, or detergent extraction and then subjected to

chromatographic separation. Material recovered in void or elution peaks comprising one or more potential protective antigens may be used in vaccine formulations.

Alternatively, genes encoding one or more potential protective antigens may be
5 cloned into a variety of expression vectors suitable for antigen production. These may include bacterial or eukaryotic expression systems, for example *Escherichia coli*, *Bacillus spp.*, *Vibrio spp.* *Saccharomyces cerevisiae*, mammalian and insect cell lines. Antigens may be recovered by conventional extraction, separation and/or chromatographic procedures.

10

ANTIGENIC DETERMINANT

Preferably the agent is an antigenic determinant.

15 The term "antigenic determinant" as used herein refers to a site on an antigen which is recognised by a T-cell receptor or an antibody. Preferably it is a short peptide derived from or as part of a protein antigen. However the term is also intended to include peptides with glycopeptides and carbohydrate epitopes. The term also includes modified sequences of amino acids or carbohydrates which stimulate responses which
20 recognise the whole organism.

It is advantageous if the antigenic determinant is an antigenic determinant of an infectious agent (such as a bacterium or virus) which causes the infectious disease.

25 **VIRAL ANTIGENIC DETERMINANT**

The antigenic determinant may be derived from pathogenic viruses. These include but are not limited to Human Immunodeficiency Virus (HIV) (GP-120, p17, GP-160 antigens), influenza (NP, HA antigen), herpes simplex (HSVdD antigen), human
30 papilloma virus, equine encephalitis virus, hepatitis (Hep B Surface Antigen), feline leukaemia virus, canine distemper, rabies virus, epstein barr virus (EBV), influenza virus.

By way of example, if the infectious agent is EBV, the antigenic determinant may be an antigenic determinant of gp340 or gp350 or of a latent protein, such as, for example, EBNAs 1,2 3A, 3B, 3C and -LP, LMP-1, -2A and 2B or an EBER.

- 5 If the infectious agent is an influenza virus, the antigenic determinant may be derivable from an internal protein (for example, nucleoprotein) or the antigenic determinant may be derivable from a viral coat protein, such as, for example, haemagglutinin and neuraminidase.
- 10 Preferably the antigenic determinant of an immediate early, early or late gene product of a virus, such as the herpes virus.

15 Preferably the antigenic determinant is derivable from an internal protein (for example, nucleoprotein) or a viral coat protein, such as, for example, haemagglutinin and neuraminidase.

BACTERIAL ANTIGENIC DETERMINANT

If the infectious agent is selected from the group consisting of enteropathogenic, 20 enterotoxigenic, enteroinvasive, enterohaemorrhagic and enteroaggregative *E.coli*, then the antigenic determinant may be an antigenic determinant of a bacterial toxin or adhesion factor.

25 The antigenic determinant may also be derived from pathogenic bacteria which include but are not limited to Chlamydia, Mycobacteria, Plasmodium Falciparum, and Legionella. Pathogenic protozoans include but are not limited to malaria, Babesia, Schistosoma, Toxoplasma and Toxocara canis.

TUMOUR ASSOCIATED ANTIGENIC DETERMINANTS

30 Alternatively, the antigenic determinant may also be derived from pathogenic agents derived from tumour cells which multiply unrestrictedly in an organism and may thus lead to pathological growths. Examples of such pathogenic agents are described in Davis, B.D. *et al* (Microbiology, 3rd ed., Harper International Edition). These

antigenic determinant may include tumour associated antigens (TAA) which can serve as targets for the host immune system and elicit responses which result in tumour destruction. Examples of such antigens include but are not limited to MART-1 (Melanoma Antigen Recognised by T cells-1) MAGE-1, MAGE-3, ST4, gp100, 5 Carcinoembryonic antigen (CEA), prostate-specific antigen (PSA), MUCIN (MUC-1), tyrosinase.

There are a number of known methods by which it is possible to identify antigenic determinants for a given antigenic agent. For example, potential protective antigens 10 may be identified by elevating immune responses in infected or convalescent patients, in infected or convalescent animals , or by monitoring *in vitro* immune responses to antigen containing preparations.

Other TAAs may be identified, isolated and cloned by methods known in the art such 15 as those disclosed in U.S. Patent No. 4,514,506.

DELIVERY OF MUTANT AND AGENT

The mutant and agent of the present invention may be linked to form a single entity.

LINKED

As used herein, the term “linked” which is synonymous with the term “coupled” means the mutant and agent may be linked by a variety of methods to facilitate the 25 translocation of the agent to the target cell, preferably into the cytosol and/or the nucleus of a mammalian target cell.

The term “linked” or “linkage” includes but is not limited to genetic linkage and chemical conjugation. The linkage of the mutant with the agent also includes but is 30 not limited to direct linkage (such as by an ionic or a covalent bond) or indirect linkage, for example, by the provision of suitable spacer groups. By way of example, the agent and the mutant may be covalently linked, to form a single active moiety/entity. The mutant and/or agent may also be linked to another entity.

CHEMICAL LINKAGE

In one embodiment of the present invention, the mutant of the present invention is chemically conjugated to the agent. Preferably the mutant is conjugated to the agent 5 using a bifunctional cross-linking reagent, such as a heterobifunctional cross-linking reagent. More preferably the cross-linking agent is N- γ (-maleimido-butyroxy)-succinimide ester (GMBS) or N-succinimidyl-(3-pyridyl-dithio)-propionate (SPDP).

Even more preferably, the agent is conjugated to EtxB by the use of the chemical 10 bifunctional cross-linker N-(gamma-maleimido-butyryl-oxy) succinimide (GMBS)(Pierce).

GENETIC LINKAGE

15 In another embodiment of the present invention, the mutant and agent are genetically linked either directly to form a fusion protein or indirectly, by for example, spacers or insulators. Preferably the agent such as an antigen or antigenic determinant, is genetically linked to amino or the C-terminus of the mutant form of the B subunit.

20 Preferably, the fusion protein comprises an antigen or an antigenic determinant which is fused to the mutant of the present invention. The antigen or antigenic determinant may be attached to either the amino or carboxy terminus of the mutant.

LINKAGE TO ENHANCE CTL ACTIVATION

25 In one preferred embodiment of the present invention, the mutant of the present invention, which targets vesicular internalisation mediated by GM1-binding may be linked, by for example, conjugation with an agent, such as an antigen or an antigenic determinant, to upregulate the presentation of the antigen or the antigenic determinant, 30 or the antigenic determinant derived from said antigen, by MHC class I molecules to stimulate appropriate CTL responses. The stimulation of CTL responses is particularly useful in the prevention and treatment of viral infections, such as, for example influenza and in stimulating responses to a tumour associated antigen (TAA).

CYTOTOXIC T LYMPHOCYTES (CTLs)

As used herein, the term “Cytotoxic T lymphocytes (CTL)” is used to refer to CTLs which are typically induced or stimulated by the display of a cell surface recognition structure, such as a processed, pathogen-specific peptide, in conjunction with MHC class I on an MHC class I bearing antigen presenting cell (APC). CTLs may function in more than one way. The best known function is the killing or lysis of target cells bearing peptide antigen in the context of an MHC class I molecule. Hence the reason why these cells are termed cytotoxic T lymphocytes (CTL). However, another function, perhaps of greater protective relevance in certain infections is the ability of CTLs to secrete interferon gamma (IFN- γ). Thus, assays of lytic activity and of IFN- γ release are both of value in measuring CTL as an indicator of the cellular immune response.

15 ANTIGEN PRESENTING CELL (APC)

As used herein, the term “antigen presenting cell” refers to any cell which is an MHC class I bearing cell. Examples of APCs include but are not limited to hematopoietic stem cells, lymphocytes, vascular endothelial cells, respiratory epithelial cells, keratinocytes, skeletal and cardiac muscle cells, neurons, cancer cells respiratory airway epithelial cells, hepatocytes, muscle cells, cardiac myocytes, synoviocytes, primary mammary epithelial cells and post-mitotically terminally differentiated non-replicating cells such as macrophages or neurons and professional antigen presenting cells (APC) such as dendritic cells or macrophages.

25

PROFESSIONAL ANTIGEN PRESENTING CELL (APC)

As used herein, the term “professional antigen presenting cell” refers to a cell, such as a dendritic cell or macrophage, that recognises an antigen to be targeted for neutralisation. The APC takes up the antigen and processes it, incorporating the antigen fragments into its own membrane and presenting them in association with either class I or class II major histocompatibility complex (MHC) molecules to T

lymphocytes, such as CTLs or T helper cells (Th) which are then stimulated to mount a response.

TARGET CELLS

5

The mutant of the present invention may be used to deliver one or more agent(s) to a target mammalian cell.

10 The term "target cell" includes but is not limited to macrophages, endothelial cells or combinations thereof. Further examples include but are not limited to antigen presenting cells (APCs) such as hematopoietic stem cells, lymphocytes, vascular endothelial cells, respiratory epithelial cells, keratinocytes, skeletal and cardiac muscle cells, neurons, cancer cells respiratory airway epithelial cells, hepatocytes, muscle cells, cardiac myocytes, synoviocytes, primary mammary epithelial cells and 15 post-mitotically terminally differentiated non-replicating cells such as macrophages or neurons and professional antigen presenting cells (APC) such as dendritic cells or macrophages.

In a preferred embodiment, the target cell is a vertebrate cell.

20

In a preferred embodiment, the target cell is a mammalian cell.

In a highly preferred embodiment, the target cell is a human cell.

25

As used herein, the term "mammal" includes but is not limited to humans, primates, rats, mice, guinea pigs, rabbits, horses, cows, sheep, pigs, goats and the like.

PHARMACEUTICAL COMPOSITIONS

30

The present invention also provides a pharmaceutical composition comprising administering a therapeutically effective amount of the substance of the mutant and agent and a pharmaceutically acceptable carrier, diluent or excipients (including combinations thereof).

The pharmaceutical compositions may be for human or animal usage in human and veterinary medicine and will typically comprise any one or more of a pharmaceutically acceptable diluent, carrier, or excipient. Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical art, and are described, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Co. (A. R. Gennaro edit. 1985). The choice of pharmaceutical carrier, excipient or diluent can be selected with regard to the intended route of administration and standard pharmaceutical practice. The pharmaceutical compositions may comprise as - or in addition to - the carrier, excipient or diluent any suitable binder(s), lubricant(s), suspending agent(s), coating agent(s), solubilising agent(s).

Preservatives, stabilizers, dyes and even flavoring agents may be provided in the pharmaceutical composition. Examples of preservatives include sodium benzoate, sorbic acid and esters of p-hydroxybenzoic acid. Antioxidants and suspending agents may be also used.

There may be different composition/formulation requirements dependent on the different delivery systems. By way of example, the pharmaceutical composition of the present invention may be formulated to be delivered using a mini-pump or by a mucosal route, for example, as a nasal spray or aerosol for inhalation or ingestable solution, or parenterally in which the composition is formulated by an injectable form, for delivery, by, for example, an intravenous, intramuscular or subcutaneous route. Alternatively, the formulation may be designed to be delivered by both routes.

Where the agent is to be delivered mucosally through the gastrointestinal mucosa, it should be able to remain stable during transit though the gastrointestinal tract; for example, it should be resistant to proteolytic degradation, stable at acid pH and resistant to the detergent effects of bile.

Where appropriate, the pharmaceutical compositions can be administered by inhalation, in the form of a suppository or pessary, topically in the form of a lotion, solution, cream, ointment or dusting powder, by use of a skin patch, orally in the form of tablets containing excipients such as starch or lactose, or in capsules or ovules either alone or in admixture with excipients, or in the form of elixirs, solutions or

suspensions containing flavouring or colouring agents, or they can be injected parenterally, for example intravenously, intramuscularly or subcutaneously. For parenteral administration, the compositions may be best used in the form of a sterile aqueous solution which may contain other substances, for example enough salts or 5 monosaccharides to make the solution isotonic with blood. For buccal or sublingual administration the compositions may be administered in the form of tablets or lozenges which can be formulated in a conventional manner.

ADMINISTRATION

10

Typically, a physician will determine the actual dosage which will be most suitable for an individual subject and it will vary with the age, weight and response of the particular patient. The dosages below are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited.

15

The compositions of the present invention may be administered by direct injection. The composition may be formulated for parenteral, mucosal, intramuscular, intravenous, subcutaneous, intraocular or transdermal administration.

20

The term "administered" includes delivery by non-viral techniques. Non-viral delivery mechanisms include lipid mediated transfection, liposomes, immunoliposomes, lipofectin, cationic facial amphiphiles (CFAs) and combinations thereof. The routes for such delivery mechanisms include but are not limited to mucosal, nasal, oral, parenteral, gastrointestinal, topical, or sublingual routes.

25

The term "administered" includes but is not limited to delivery by a mucosal route, for example, as a nasal spray or aerosol for inhalation or as an ingestable solution; a parenteral route where delivery is by an injectable form, such as, for example, an intravenous, intramuscular or subcutaneous route.

30

KITS

The present invention further provides kits comprising the mutant and the agent. In one embodiment of the present invention, the mutant and agent are presented as a single active moiety. Such kits may be used to treat the diseases and conditions of the present invention.

In one preferred embodiment of the present invention, the agent in the kit may comprise an antigen and/or antigenic determinant and/or a separate adjuvant for coadministration with said composition. Alternatively, the agent in the kit comprises an antibody.

DISORDERS

15 The mutant of the present invention may be used to deliver an agent to treat disease such as infectious diseases and or viral infections and/or cancer.

TREATMENT

20 It is to be appreciated that all references herein to "treatment" include one or more of curative, palliative and prophylactic treatment. In particular, the term "treatment" includes but is not limited to pre- disease treatment and post-disease treatment. By way of example, a subject in a pre- disease state may be treated to prevent the onset and/or progression of that disease.

25 Preferably, the term treatment includes at least curative treatment and/or palliative treatment.

The treatment may be for treating conditions associated with a particular disease state.

30 As with the term "treatment", the term "therapy" includes curative effects, alleviation effects, and prophylactic effects.

The therapy may be on humans or animals.

The therapy may be for treating conditions associated with cancer.

INFECTIOUS DISEASES

5 Examples of infectious diseases of the present invention include but are not limited to HSV-1, HSV-2, EBV, VZV, CMV, HHV-6, HHV-7 and HHV-8, hepatitis A, B, C, D and E, Neisseria meningitidis, Haemophilus influenzae type B and Streptococcus pneumoniae, Legionella pneumophila and Mycobacterium tuberculosis, Neisseria gonorrhoeae, HIV-1, HIV-2 and Chlamydia trachomatis, E.coli, rotavirus, 10 Salmonella enteritidis, Salmonella typhi, Helicobacter pylori, Bacillus cereus, Campylobacter jejuni and Vibrio cholerae, Staphylococcus aureus, Streptococcus pyogenes and Streptococcus mutans, malaria, Trypanosoma spp., Toxoplasma gondii, Leishmania donovani and Oncocerca spp.

15 CANCER RELATED DISEASES

The mutant and agent of the present invention can be introduced into a mammal either prior to any evidence of cancers such as melanoma or to mediate regression of the disease in a mammal afflicted with a cancer such as melanoma. Cancers of mammals 20 which may be treated using the composition of the present invention include but are not limited to melanoma, metastases, adenocarcinoma, thymoma, lymphoma, sarcoma, lung cancer, liver cancer, colon cancer, non-Hodgkins lymphoma, Hodgkins lymphoma, leukemias, uterine cancer, breast cancer, prostate cancer, ovarian cancer, cervical cancer, bladder cancer, kidney cancer, pancreatic cancer and the like.

25 If the mammal to be treated is already afflicted with cancer or metastatic cancer the mutant and agent can be administered in conjunction with other therapeutic treatments. In this context, the present invention encompasses combination therapy. By combination therapy is meant that the mutant and the agent of the present invention is administered to the patient in combination with other exogenous immunomodulators or immunostimulatory molecules, chemotherapeutic drugs, antibiotics, antifungal drugs, antiviral drugs and the like alone or in combination 30 thereof. Examples of other exogenously added agents include but are not limited to

exogenous IL-2, IL-6, interferon, tumour necrosis factor, cyclophosphamide, and cisplatinum, gancyclovir and amphotericin B.

5 In one preferred embodiment, the agent is released from the B subunit after delivery into the cell.

In another preferred embodiment, preferably the linkage of the mutant-agent conjugate may be chosen so that the agent is specifically delivered into the nucleus of a target cell.

10 In another preferred embodiment, the simultaneous, separate or sequential combination of mutant B subunit may be used to deliver an agent to a target cell and a wild type B subunit may be used to deliver an agent to a target cell.

15 EXAMPLES

The present invention will now be described only by way of example in which reference is made to the following Figures:

20 In this regard:

Figure 1 is a graph;

Figure 2 is a graph;

25

Figure 3A is a pictorial representation;

Figure 3B is a graph;

30

Figure 4A is a pictorial representation;

Figure 4B is a graph;

Figure 4C is a graph;

Figure 5 is a pictorial representation;

Figures 6A, 6B, 6C are pictorial representations;

5 Figures 6D and 6E are graphs;

Figures 7A and 7B are graphs;

Figures 8A and 8B are graphs;

10 Figures 9A, 9B, 9C, 9D, 9E, 9F, 9G and 9H are graphs;

Figures 10A – 10T are graphs; and

15 Figure 11 is a pictorial representation.

In more detail:

Fig.1 Ctx(H57A) exhibits a severe defect in toxicity. Time course of electrogenic

20 Cl⁻ secretion induced by the addition of 2 nM Ctx (□) or Ctx(H57A) (◆) to the apical surface of T84 cell monolayers (with data points representing the mean ± S.E., where n=2 independent monolayers). Three independent experiments gave similar results.

Fig.2 CtxB(H57A) retains the ability to bind to GM1. CtxB (■), CtxB(H57A) (5)

25 or EtxB(G33D) (•) at a concentration of 1μg/ml were serially diluted 3-fold in GM1-coated microtiter plates and the bound B-subunits detected by immunoassay as described in the Methods. Three independent experiments gave similar results.

Fig.3 CtxB(H57A) interaction with CD8+ T-cells. Isolated CD8+ T-cells derived

30 from the MLN were incubated on ice for 1 hour in the absence (PBS control) or presence of 100nM CtxB, CtxB(H57A) or EtxB(G33D), then labelled with either anti-CtxB or anti-EtxB antibodies followed by a goat anti-mouse IgG-FITC secondary conjugate. Cells were analysed by fluorescence microscopy (A) or flow cytometry

(B). The flow cytometric trace obtained for PBS treated cells is shown in red and the trace obtained for cells treated with the various B subunits is overlaid in black.

Fig.4 CtxB(H57A) is defective in triggering CD8+ T-cell apoptosis. *A.* MLN cells were cultured for 48 hours in the absence (PBS control) or presence of 100nM CtxB, CtxB(H57A) or EtxB(G33D), then stained with anti-CD8(PE) and anti-CD4(FITC) antibodies and analysed by flow cytometry. The percentage of CD8+ T-cells is shown in the lower right hand quadrant. *B.* MLN cells were cultured in the presence of CtxB or CtxB(H57A) at concentrations ranging from 10 nM to 2.5 μ M, and labelled and analysed as above. The percentage of surviving CD8+ T-cells, compared with PBS treated control cells, was calculated. *C.* Isolated CD8+ T-cells derived from the MLN were cultured for 18 hours in the absence (PBS control) or with 3.45 μ M CtxB, CtxB(H57A) or EtxB(G33D), then stained with propidium iodide and analysed by flow cytometry to determine the percentage of cells containing sub-diploid DNA.

Fig.5 Superimposed crystal structures of wild-type CtxB and CtxB(H57A). *(A).* Superposition of the crystal structure of wild-type CtxB (green) complexed with GM1-OS (blue) onto the structure of the CtxB(H57A) mutant (yellow) complexed with galactose (red). A single receptor-binding site (site H) of the five independent sites is shown. Electron density for the galactose molecule is shown at 2 σ contours in an ($mF_{\text{obs}} - F_{\text{calc}}$) omit map. The point of maximal difference between the peptide backbones of the wild-type and mutant toxins is at residue Gln 56, where the respective C α atom positions differ by 7 \AA . *(B).* Superposition of the wild-type cholera toxin B-pentamer in complex with the receptor oligosaccharide onto the CtxB(H57A) mutant B-pentamer. The molecular surface of wild-type CTB is shown in green (50-60 loop) and blue. The GM1-oligosaccharide is shown in red. The molecular surface of the H57A mutant is shown in yellow (50-60 loop). The terminal galactose residue of the GM1-oligosaccharide is not visible behind the molecular surface of the 50-60 loop which forms one side of its binding site on the protein. At one of the five binding sites the molecular surface of this loop is not shown, so that the underlying protein conformation may be seen.

Figure 6: Production and characterisation of the EtxB-26mer conjugate. Panel A: SDS-PAGE analysis of EtxB-26mer conjugate. Lanes: 1, EtxB unheated; 2, EtxB boiled; 3, EtxB-26mer, unheated; 4, EtxB-26mer, boiled. Molecular weight standards in kDa and EtxB monomer and pentamer (upper and lower arrows, respectively) are indicated. Panel B and C: Western blot analyses of the same samples probed with mAb 118-8, specific for EtxB (Panel B) or a polyclonal antiserum specific for SIINFEKL peptide (Panel C). Panel D and E: GM1 binding properties of EtxB-26mer conjugate. Serial dilutions of EtxB and EtxB-26mer were applied to GM1-coated ELISA plates and detected using mAb 118-8 (Panel D) or anti-SIINFEKL (Panel E) as above. Absorbances were plotted against the dilution factor and are given as mean ± SD.

Figure 7: EtxB-mediated delivery of the 26mer peptide into the class I presentation pathway. Panel A: Extent of peptide presentation was assessed by analysis of IL-2 release by RF33.70 T-cell hybridoma. JAWSII dendritic cells were incubated with various concentrations of either 8mer or 26mer peptide alone, EtxB and 26mer peptide admixed, or EtxB-26mer conjugate for 2h. Concentrations tested were equivalent to the molar concentration of peptide in each sample at 1 pM, 10 pM, 100 pM, 1 nM, 20 nM, 40 nM, 60 nM, 80 nM, and 100 nM, respectively. PBS was used as control. Cells were then fixed with 1% (w/v) paraformaldehyde and incubated overnight with RF33.70 cells. The IL-2 content of harvested medium was determined by ELISA. Duplicate samples were tested and the data are given as mean ± SD. Panel B: Detection of MHC-I/SIINFEKL complexes as assessed by FACS analysis using mAb 25D1.16. JAWSII cells were treated with 100 nM 8mer peptide (dashed black curve), EtxB-26mer conjugate (solid black curve), or PBS (grey filled curve) for 2 h and then sequentially incubated with mAb 25D1.16 and a FITC-labelled secondary antibody followed by flow cytometric analysis.

Figure 8: EtxB-mediated peptide delivery: Optimisation and kinetics of presentation. Panel A: Effect of truncating or extending the 26-mer peptide on the extent and efficiency of EtxB-mediated presentation of the class I epitope. JAWSII cells were incubated for 2 h with the indicated peptides either alone, or admixed with or conjugated to EtxB at equivalent peptide concentrations of 100 nM. Cells were then

fixed with 1% (w/v) paraformaldehyde and antigen presentation assessed by incubating the cells with RF33.70 T-cell hybridoma and determining the IL-2 content of harvested medium using ELISA. Panel B: Assessment of the kinetics of class I peptide presentation. JAWSII cells were incubated with EtxB-conjugates for the indicated time intervals, fixed with 1% (w/v) paraformaldehyde and antigen presentation was assessed as above. Duplicate samples were tested and the data given as mean ± SD.

Figure 9: Effect of inhibitors on EtxB-mediated delivery and presentation of class I peptides. The effects of 200 nM Baflomycin A1 (BafA1), 10 µM Brefeldin A (BFA), and 10 µM epoxomicin on EtxB-mediated delivery of the 19mer and 31mer peptide were assessed in both IL-2 release assays (Panel A-D) and FACS analysis using the 25D1.16 antibody (Panel E-H). Unconjugated 8mer peptide and PBS were used as positive and negative controls, respectively. IL-2 release data are given as mean ± SD. In panels D-F, EtxB-19mer (solid black curve), EtxB-31mer (dashed black curve), and PBS (grey filled curve) are shown.

Figure 10: EtxB-mediated delivery of class I peptides: Evidence for trafficking into the Golgi compartment and proteasome involvement. Panel A: Confocal microscopic analysis of the cellular localisation of EtxB and MHC-I/SIINFEKL complexes upon treatment of JAWSII cells with EtxB-19mer for 1 min (image e-g) or 120 min (image i-k), or with EtxB-31mer for 1 min (image h) or 120 min (image l). Control cells were treated with PBS for 120 min (image a-d). All cells were fixed with paraformaldehyde, and stained with a polyclonal rabbit antiserum specific for EtxB, and the 25D1.16 mAb specific for MHC-I/SIINFEKL-complexes, followed by FITC- or TRITC-conjugated secondary antibodies as described in Materials & Methods. Cell nuclei were stained with DAPI (blue). For EtxB-19mer both separate and overlayed images are shown whereas for the EtxB-31mer only the overlayed image is shown. Panel B: Co-localisation of MHC-I/SIINFEKL complexes with wheat germ agglutinin (WGA) and the effect of epoxomicin, a proteasome inhibitor on MHC-I loading. Cells were treated for 120 min with EtxB-19mer (image a-c) or EtxB-31mer (image d) as above, fixed with paraformaldehyde followed by incubation with rhodamine-labelled WGA and mAb 25D1.16 and a FITC-labelled secondary antibody. For EtxB-19mer

both separate and overlayed images are shown whereas for the EtxB-31mer only the overlayed image is shown. An identical experiment to that shown in images a-d above was carried out with 10 µM epoxomicin added to the cells 60 min prior to addition of the EtxB conjugates (image e-h).

5

Figure 11: Figure 11 shows uptake of wild-type EtxB and two mutants EtxB(H57A) and EtxB(H57S) into Jurkat T-cells. In addition and as a control, a mutant which does not bind to GM1 at all, EtxB(G33D) was tested. Cells were stained with an antibody against the B-subunit (anti-EtxB), or with rhodamine labelled wheat germ agglutinin (a marker for the Golgi - anti-Golgi), with the nuclear stain DAPI, and the images superimposed (right hand side). It is evident that EtxB, EtxB(H57A), and EtxB(H57S) traffic into cells into a perinuclear compartment that co-localises with the Golgi marker wheat germ agglutinin. Thus, it is clear that EtxB(H57A) and EtxB(H57S) are capable of functioning as drug targetting molecules even though they no longer retain their immunomodulatory properties.

MATERIALS & METHODS (Part I - Example 1-5)

Alanine-scanning mutagenesis and gene manipulation

Ala-substitutions were introduced into the V52 to I58 loop of CtxB by PCR mutagenesis (20). Plasmid pATA14 (21), a pBluescript IIKS derivative containing a reconstructed *ctxAB* operon with an engineered *Eco*RI site at the 3'-end of the *ctxA* gene, was used as a PCR template. PCR fragments, with appropriately engineered substitutions in *ctxB*, were ligated into the *Eco*RI-*Spe*I sites of pATA14, thereby replacing the wild-type *ctxB* gene with a mutant allele. The resultant plasmids, pATA16 to pATA22, were confirmed by DNA sequencing to encode Ala substitutions at residues 52 to 58 in CtxB, respectively.

Plasmid pCDR3, was constructed by subcloning the *Eco*RV-*Spe*I fragment containing the entire *ctxAB* operon of pATA14, into the controlled expression vector pTTQ18 (21).

To facilitate subsequent purification and characterisation of wild-type and mutant B-subunits (devoid of any A-subunit), the *ctxB* gene from pATA14 and the mutant *ctxB* allele of pATA21 were subcloned into *Eco*RI-*Spe*I digested pTRH64 (13), a broad host-range controlled expression vector derived from pMMB66EH (22). The 5 resultant plasmids were designated pATA13 (encoding wild type CtxB) and pATA29 (encoding the mutant B-subunit, CtxB(H57A)).

Periplasmic extraction

Periplasmic extracts from *E. coli* XL1-Blue (Stratagene) harbouring plasmids 10 pATA14, or pATA16 to pATA22 were prepared as described in (23) and immediately dialysed against Hank's balanced salt solution (HBSS; Sigma, MO) containing 10 mM HEPES pH 7.4, and then flash frozen and stored at -80°C prior to electrophysiologic analysis.

Purification of proteins

Plasmids pCDR3 and pATA21 encoding Ctx holotoxin and Ctx holotoxin (with an H57A mutation in the B-subunit (Ctx(H57A))), respectively were electroporated into *V. cholerae* 0395NT (that contains an engineered chromosomal *ctxAB* deletion) and the toxins purified as previously reported (21). Plasmids pATA13 and pATA29 20 encoding wild-type CtxB and CtxB(H57A) respectively were mobilised into the non-pathogenic *Vibrio* sp. 60 strain, and the B-subunits purified from the culture media using the method reported in (7). EtxB(G33D) was purified from *Vibrio* sp 60 (pTRH64) as reported previously (13). Purified B-subunit preparations were applied to a detoxigel column (Pierce), and the eluted fractions pooled, dialysed against PBS. 25 Protein concentration determined as reported in (24) and LPS content shown to be to be >30EU mg-1 protein (BioWhittaker).

Crystallographic structure determination

Crystals of CtxB(H57A) were grown from hanging drops by vapor diffusion 30 equilibration against a well buffer solution containing 50 mM NaCl, 100 mM Tris-HCl pH 8.4 and 32% (w/v) PEG 5000. Drops consisted of 1 µl of protein at 3 mg/ml in 100mM Tris-HCl pH 7.5, 1 µl 300 mM galactose (β -d-galactopyranoside), and 1 µl well buffer. Crystals formed in space group P2₁2₁2 (a=101.4 Å b=114.7 Å c=45.6 Å)

with one pentamer per asymmetric unit. Diffraction intensities to 2.0 Å resolution were measured from a single flash-frozen crystal using 12 keV radiation from APS beamline 19ID and a 3Kx3K CCD detector in binned mode. The initial crystallographic model consisted of the previously determined CtxB(H94R) structure 5 ((25); PDB accession code 3chb) positioned by molecular replacement. After rigid body refinement of the constituent monomers, the model for residues 50-62 of each subunit was rebuilt manually. Iterative positional and B-factor refinement, alternating with manually refitting, yielded crystallographic residuals $R = 0.253$, $R_{free} = 0.317$. At this point, difference density for bound galactose was clear in 2 of the 5 subunits. 10 Continued refinement with incremental addition of discrete water molecules and 2 additional galactose molecules yielded a model with $R = 0.191$, $R_{free} = 0.252$. The final stages of refinement included 446 discrete water molecules, 4 galactose molecules, and a riding-hydrogen model, yielding final crystallographic residuals $R = 0.179$, $R_{free} = 0.239$ with excellent stereochemistry. The mean estimated standard 15 uncertainty in atomic coordinates based on Cruickshank's DPI measure was 0.19 Å. Intensity data were merged and scaled using programs denzo, scalepack, and truncate (26, 27). Model fitting and real-space optimization used the program Xfit (28), while all remaining refinement used the program Refmac (27). Figures were prepared using programs MSMS (29) and Raster3D (30). The final model has been deposited with 20 the Protein Data Bank, accession code 1g8z.

Electrophysiology

T84 cells (from passage 80) obtained from the ATCC were grown and passaged as described (31). Toxins were diluted in prewarmed Hank's balanced salt solution 25 (HBSS; Sigma, MO) and 10 mM HEPES pH 7.4, and applied to the apical surface of confluent T84 cell monolayers in Transwell inserts (Costar, Cambridge, MA), followed by incubation at 37°C. Measurements of short circuit current (I_{sc}) and resistance (R) were performed as reported elsewhere (31).

Toxin-receptor interaction

GM1-enzyme linked immunosorbent assay. Toxin B-subunit interaction with GM1 was monitored on microtiter plates (Immulon 1, Dynatech, USA) coated with 1.5 µg/ml GM1 (Sigma) in PBS as reported previously (13), using LT39 (32), a

monoclonal antibody that detects both CtxB and EtxB, or 118-8, a monoclonal antibody that detects EtxB (33).

Surface plasmon resonance. Liposomes were prepared from 2 ml of 5 mole % GM1:

5 95 mole % 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) in choloroform-methanol (2:1). The glycolipid:lipid mixture was allowed to evaporate under vacuum and then dissolved in PBS and passed through a polycarbonate filter (50 nm pore size) using the LipoFast Basic System (Avestin Inc., Glen Creston Ltd, Middlesex, England) as recommended by the manufacturer and described by

10 Kuziemko et al. (1996). A BIACore 1000 (Pharmacia) was employed to coat an HPA sensor chip (Biocore, Herts, England) with GM1-containing liposomes, and B-subunit K_D binding measurements were obtained as reported previously (34).

Lymphocyte isolation and culture

15 Mesenteric lymph nodes and spleens were removed from 6-10 week old NIH mice bred under SPF conditions (University of Bristol) and the tissues crushed under wire mesh. The cells were then washed three times in Hanks medium without calcium and magnesium (Gibco BRL) + 20 mM HEPES (Sigma-Aldrich). Red blood cells were lysed by the addition of 0.5 ml Ack Lysing buffer (BioWhittaker) for 30 seconds. For
20 the purification of specific lymphocyte populations, cells were washed in PBS containing 0.5% (w/v) BSA and 5 mM EDTA (BDH laboratory supplies, Poole), prior to the addition of specific antibodies conjugated with MACS microbeads (Miltenyi Biotec, Germany) for 35 min on ice. CD8+ T-cells were negatively selected using anti-CD4 and anti-B220. B-cells were negatively selected using anti-CD43. Labelled
25 cell suspensions were applied to VS selection columns (Miltenyi Biotec) and the negative fractions eluted with 0.5% (w/v) BSA-PBS containing 5 mM EDTA and used immediately.

MLN cells, purified CD8+ T-cells and B-cells were cultured at 37°C in 5% CO₂ at a
30 concentration of 2x10⁶/ml in α-modified Eagles Medium (Gibco) for MLN and CD8+ T-cells and RPMI 1640 medium (Gibco) for B-cells, both supplemented with 20 mM HEPES, 4 mM L-glutamine, 100 IU/ml penicillin, 100 µg/ml Streptomycin, 5x10⁻⁵ M 2-Mercaptoethanol and 5% (v/v) foetal calf serum (Sigma). MLN and B-cells were

cultured for 48 hours, or CD8+T-cells for 18 h, in the absence or presence of either wild-type or mutant B subunits at the concentrations specified. In some experiments, treated cells were resuspended in Hanks medium supplemented with 20 mM HEPES 5 0.02% (w/v) sodium azide, 10% (v/v) rat serum and either incubated for 30 min on ice with rat anti-mouse CD8 α -PE (PharMingen) and rat anti-mouse CD4-FITC (PharMingen) or stained with propidium iodide (Sigma) and then analysed by flow cytometry, as previously described (14).

Immunfluorescent staining

10 Isolated CD8+ T-cells (2×10^6) were incubated on ice in PBS with 100 nM wildtype or mutant B subunits for 1 hour. Treated cells were analysed by immunofluorescence microscopy and flow cytometry to detect bound B-subunit. For immunofluorescence microscopy, treated cells were washed in ice cold PBS, overlaid onto cover slips pre-coated with poly-L-lysine (Sigma), fixed (3.7% (v/v) formaldehyde, 4°C, 4 min; 15 methanol, -20°C, 5 min) and labelled with anti-EtxB or anti-CtxB antibodies, followed by FITC-goat anti-mouse IgG (DAKO A/S Denmark). The cover slips were mounted using Mowiol mounting medium + 2.5% (w/v) DABCO (Sigma) and analysed using a Zeiss Axioskop fluorescence microscope. In a parallel experiment the cells were labelled with the same antibodies and analysed by flow cytometry.

20

Immunizations

Anti-CtxB responses in NIH mice following subcutaneous immunization with either 2 x 30 μ g of B-subunit or intranasal immunization with 3 x 10 μ g B-subunit were determined by using GM1-microtiter plates coated with 1 μ g/ml CtxB as reported 25 previously (13).

Example 1(a)

Alanine scanning mutagenesis of the conserved V52 to I58 loop in cholera toxin B-subunit.

Residues V52 to I58 of the B-subunit of cholera toxin were subjected to alanine scanning mutagenesis to assess whether this region, which comprises a conserved.

flexible loop, plays an important role in cholera toxin action. To facilitate the construction and analysis of the various mutant Ctx proteins, the *ctxA* and *ctxB* genes were firstly PCR amplified as separate cistrons and then ligated to reconstruct a *ctx* operon with a conveniently situated *Eco*RI site at the fusion junction. As a consequence, a Lys to Arg substitution was introduced at residue 237 in the mature CtxA-subunit resulting in an alteration in the C-terminal -KDEL sequence, to yield -RDEL (which is identical to the C-terminus normally found in the A-subunit of *E. coli* enterotoxin).

10 **Results 1(a)**

This substitution in CtxA was demonstrated not to alter the A-subunit's intrinsic ADP-ribosyltransferase activity or the kinetics and magnitude of toxin-induced Cl⁻ secretion in polarized T84 epithelial cells (21).

15

Example 1(b)

Plasmid pATA14, encoding CtxA^(RDEL)CtxB (hereafter referred to as Ctx), was subjected to site-directed mutagenesis to introduce individual Ala substitutions at 20 residues from V52 to I58 in CtxB, as described in the Materials & Methods.

Results 1(b)

When crude periplasmic extracts from *E. coli* strains expressing these mutant Ctx toxins were evaluated for their capacity to induce Cl⁻ secretion by T84 cells it was found that one of the mutants containing a His to Ala substitution at residue 57 had an apparent severe toxicity defect (see below).

Example 1©

30

To further investigate this and in particular to evaluate the impact of the H57A mutation on B-subunit function, both the mutant holotoxin, Ctx(H57A) and recombinant B-subunits, CtxB(H57A), devoid of contaminating A-subunit, were purified and their identity confirmed by mass spectrometry.

Results 1©

Prior to assessing the functional properties of the mutants, we showed that the intrinsic stability of the CtxB(H57A) pentamers were, like wild-type CtxB, 5 remarkably stable, retaining their oligomeric structure at pH's as low as 3.0 or when incubated in presence of 1% (w/v) of the ionic detergent, sodium dodecyl sulphate (data not shown).

Example 2**10 *Ctx(H57A) exhibits a severe defect in toxicity***

Purified preparations of both wild-type Ctx and Ctx(H57A) were tested for their ability to trigger chloride efflux in polarised human intestinal epithelial (T84) cells (Fig 1).

15

Results 2

Addition of 2nM Ctx to the apical surface of T84 cells resulted in a characteristic 40 min lag period followed by rapid and maximal Cl⁻ efflux, as monitored by a change in 20 short circuit current across the cell monolayer. By contrast, the addition of an equimolar concentration of Ctx(H57A) to T84 cells failed to trigger Cl⁻ efflux suggesting that the His-57 residue plays a vital role in cholera toxin action (Fig 1). The mutant displayed an almost complete lack of toxicity even at concentrations of 1000nM (data not shown).

25

Example 3***CtxB(H57A) retains the ability to bind to GM1 and to the surface of mammalian cells.*****30 *Example 3(a)***

Given that the mutation is adjacent to the receptor-binding pocket in the B-subunit, one possible explanation for the toxicity defect was that the mutant had lost the ability to bind with high affinity to GM1-ganglioside.

The binding of CtxB(H57A) to GM1 was evaluated by both ELISA and surface plasmon resonance.

Results 3(a)

5

Microtiter plates coated with GM1 were incubated with various concentrations of CtxB, CtxB(H57A) and EtxB(G33D) and bound protein detected using anti-B-subunit monoclonal antibodies (Fig. 2). CtxB and CtxB(H57A) bound to GM1-coated microtiter plates to a similar extent, with the sensitivity of detection for both subunits 10 being in the 1-2 ng/ml range (equivalent to $1.6\text{-}3.2 \times 10^{-11}\text{M}$). The K_D for interaction with GM1 was determined by surface plasmon resonance using the method of Kuziemko et al (1996) and found to be $1.9 (\pm 0.9) \times 10^{-10}\text{ M}$ for CtxB and $5.0 (\pm 3.7) \times 10^{-10}\text{ M}$ for CtxB(H57A). We therefore conclude that CtxB(H57A) retains a very high avidity for interaction with GM1.

15

Example 3(b)

20

To further investigate aspects of the function of CtxB(H57A) we assessed whether it could bind to mammalian cells. For this purpose we selected murine CD8+ T-cells, as these had previously been shown to be suitable for assessing CtxB and EtxB-mediated effects on immune cells (14). Highly purified CD8+ T-cells from the mesenteric lymph node (MLN) of NIH mice were incubated on ice with 100nM of CtxB, CtxB(H57A) or EtxB(G33D) and the bound B-subunits detected using anti-B-subunit antibodies and a FITC secondary antibody, prior to analysis by fluorescence microscopy (Fig 3A) or flow cytometry (Fig. 3B).

Results 3(b)

30

Microscopy revealed a clear halo of fluorescence around the cells incubated with both CtxB and CtxB(H57A) but not with EtxB(G33D) or cells incubated with PBS. Flow cytometry permitted a semi-quantitative measurement of B-subunit binding to the cells, since the fluorescence detected by the FACscan is directly proportional to the amount of bound secondary antibody. When control samples, using cells incubated in

PBS were analysed by the FACScan, low level background fluorescence was detected and is shown as the red line in Fig. 3B. Incubation with CtxB, CtxB(H57A), but not with EtxB(G33D), resulted in a marked increase in fluorescence intensity, indicative of B-subunit binding to CD8+ T-cells (Fig 3 B; black line). In addition, when 5 concentrations as low as 1-10 nM were tested no difference in the relative fluorescence shifts between wild-type CtxB and CtxB(H57A) were observed. We therefore conclude that CtxB(H57A) retains a high affinity for GM1 and shows a comparable level of binding to mammalian cells as wild-type CtxB.

10 **Example 4**

CtxB(H57A) lacks immunomodulatory activity

Example 4(a)

15 An unexpected property of CtxB and EtxB is their capacity to induce the selective apoptosis of murine CD8+ T-cells, involving an NF κ B-dependent and caspase-3 dependent pathway ((14); This has previously been proposed to be dependent on B-subunit interaction with GM1, since EtxB(G33D) fails to elicit such an effect (14). CtxB(H57A) was therefore tested to assess if it had retained the capacity to induce 20 CD8+ T-cell apoptosis. MLN cells were cultured for 48 h in the presence or absence of 100nM CtxB, CtxB(H57A) or EtxB(G33D), then the CD4+ and CD8+ T-cells stained with fluorescently labelled antibodies and detected by flow cytometry.

Results 4(a)

25 Fig. 4A shows that after 48 h, cells cultured with either PBS or the non-binding mutant EtxB(G33D) contained approximately 17-18% CD8+ T-cells, whilst treatment with wild type CtxB reduced the proportion of CD8+ T-cells to <6%. Strikingly, CtxB(H57A) failed to induce any CD8+ T-cell depletion above that seen for the 30 negative controls.

Example 4(b)

In order to investigate this further, MLN cell cultures were treated with 5 concentrations of B-subunit ranging from 10 nM to 2.5 μ M and CD8+ T-cell depletion assessed as before (Fig. 4B).

Results 4(b)

10 This revealed that 100 nM CtxB resulted in maximal CD8+ T-cell depletion whereas even at the highest concentration of 2.5 μ M, CtxB(H57A) showed only a modest capacity to induce depletion.

Example 4©

15 High doses of the B subunits (3.45 μ M) were also tested for their capacity to induce apoptosis in isolated CD8+ T-cells derived from the MLN. The cells were cultured for 18 h in the presence or absence of the B-subunits, and then stained with propidium iodide to reveal levels of sub-diploid DNA, indicative of apoptotic cells.

20

Results 4©

Fig 4C shows that wild-type CtxB, but not CtxB(H57A) or EtxB(G33D) increased the percentage of apoptotic cells above background. We therefore conclude that, even 25 though CtxB(H57A) binds to CD8+ T-cells, it nonetheless exhibits a severe defect in inducing their apoptosis.

Example 4(d)

30 In addition the effect of CtxB and the mutant B-subunits on activation of B-cells was investigated as it has been reported that CtxB and EtxB cause the up-regulation MHC Class II and CD25 (11, 12).

Results 4(d)

As expected, 48h treatment of isolated splenic B-cells with 1.75 μ M CtxB increased surface-expression of MHC Class II and CD25, whereas CtxB(H57A) or EtxB(G33D)
5 did not.

Example 4(e)

To investigate if the defect in modulation of immune cells *in vitro* correlated with a
10 corresponding loss in potent immunogenicity *in vivo*, mice were immunised subcutaneously or intranasally with CtxB or CtxB(H57A) as described in the Materials & Methods.

Results 4(e)

15 Subcutaneous immunisation with 30 μ g CtxB or CtxB(H57A) in PBS, on two occasions 10 days apart resulted in a 78-fold difference in mean serum anti-B-subunit IgG titers of 7000 ± 1800 and 90 ± 90 , respectively. If mice were given three 10 μ g intranasal doses of CtxB or CtxB(H57A) in PBS, on three occasions 7 days apart, the
20 mean serum anti-B-subunit titers were 125000 ± 64000 and 11000 ± 3000 , respectively. We therefore conclude that the H57A mutation causes a marked reduction in B-subunit immunogenicity.

Example 5**25 X-ray crystallographic structure of CtxB(H57A)**

To gain an insight into the structural consequences of substituting His-57, CtxB(H57A) was co-crystallized with galactose.

30 Results 5

This revealed an X-ray structure that is remarkable in several respects. The most striking alteration is the conformation of the V52-I58 loop in CtxB(H57A) which is

quite different from that found in the wild-type toxin (Fig. 5A and B). The C α atom of the mutated residue 57 is shifted by ~4Å, and the difference in the backbone position increases to ~7Å at residue Gln-56 in comparison with the structure of wild-type CtxB complexed with GM1-oligosaccharide (GM1-OS) (18, 25). Moreover, the shift is observed in all 5 subunits even though galactose is bound only to 4 of them. The net effect of the conformational change is to displace residues 52-58 towards the central pore of the toxin B-pentamer, with the result that the accessible surface of the toxin pentamer is substantially altered in this region (Fig. 5B). In the wild-type CtxB:GM1-OS complex both residues E-51 and Q-61 form direct hydrogen bonds with the terminal galactose of GM1, while residue Q-56 forms solvent-mediated hydrogen bonds with both the terminal galactose and the sialic acid of GM1. Given this, it is somewhat unexpected that such a large change in loop conformation does not disrupt, or at least perturb, sugar binding. Nevertheless, the observed galactose location in the present complex differs by only 0.4Å r.m.s. from that seen for the terminal galactose in the GM1-OS complex (Fig. 5A). We therefore would predict that regardless of the displacement of the loop the overall GM1 binding mode is essentially unperturbed by the mutation (Fig. 5B), which is in accord with our biophysical measurements of GM1 affinity.

In addition to the shift in position of the loop, residues 52-58 are well-ordered in each of the five subunits of the CtxB(H57A) structure. In a large set of previous structures determined for CtxB and EtxB in complex with various receptor analogues there has been a near-perfect correlation of order with sugar binding (19). This has been interpreted as implying that the loop is relatively flexible in the unbound toxin, becoming well-ordered as it moulds itself around the terminal galactose sugar during receptor binding. In the mutant CtxB(H57A) structure this correlation is lost: implying that the transition of the loop from a disordered to a fixed structure, that occurs when wild-type B-pentamers bind to receptors, has already occurred in the H57 mutant in the absence of bound saccharide.

Materials and Methods (Part II - Examples 6-11)

Experimental protocols on how to determine whether peptides attached to EtxB are delivered into the MHC class I pathway

5

Production and characterisation of EtxB and EtxB conjugates

Recombinant EtxB was expressed in a non-toxinogenic vibrio, *Vibrio* sp. 60, and purified as reported earlier (15). EtxB was depleted of LPS using detoxi-gel columns (Pierce, Rockford), resulting in ≤50 endotoxin units (EU) per mg EtxB, as determined in a *Limulus* amoebocyte lysate assay (BioWhittaker, Walkersville). Peptides were synthesised by solid phase synthesis and purified by reverse-phase HPLC by Dr. G. Bloomberg (Department of Biochemistry, University of Bristol). The molecular mass of each peptide was confirmed by mass spectrometry. The amino acid sequences and molecular weights of peptides used in this study are listed in Table 1.

15

TABLE 1: Peptides used in this study

Peptide	Sequence	Mw
8mer	SIINFEKL	945
9mer	CSIINFEKL	1048
16mer	CEKLAGFGSIINFEKL	1751
19mer	CAVGAGATAEESIINFEKL	1905
26mer	CEKLAGFGAVGAGATAEESIINFEKL	2608
26mer*	CEKLAGFGARGAGATAEESIINFEKL	2665
31mer	CEKLAGFGAVGAGATAEESIINFEKLTEWTS	3212

20 For conjugation of peptides to EtxB the chemical bifunctional cross-linker N-(gamma-maleimido-butyryl-oxy) succinimide (GMBS)(Pierce) was used. In brief, EtxB was first reacted with GMBS in a 1:4 molar ratio for 1 h at room temperature,

and excess GMBS removed by gel filtration on a Sephadex G-25 column (Pharmacia, Uppsala, Sweden). Fractions containing EtxB-GMBS were pooled and reacted with peptide at a 1:2 molar ratio for 2 h at room temperature. Each peptide contained an N-terminal cysteine to allow direct reaction between the free cysteine and the second reactive group in the GMBS molecule. Unreacted GMBS groups were quenched by the addition of 2-mercaptoethanol (2-ME)(Sigma, Poole, UK) to a final concentration of 50 mM and incubation at room temperature for 30 minutes. Finally, EtxB-peptide conjugates were separated from excess peptide on a Sephadex G-50 column (Pharmacia). For all peptides, an EtxB pentamer:peptide ratio of approximately 1:5 was achieved, as estimated by gel filtration on a Superdex 200 column connected to a SMART system (Pharmacia), using molecular weight standards. Conjugate concentration was determined using the D_C protein assay (BioRad, Richmond), and the molar equivalent concentration of peptide estimated from the EtxB:peptide ratio. Conjugates were analysed either boiled or unboiled on SDS-polyacyrlamide gels followed by staining with Coomassie. The immunoreactivity of conjugates was examined by Western blotting using a monoclonal antibody (mAb)(118-8) specific for EtxB pentamers and a polyclonal antiserum specific for the SIINFEKL peptide (a gift from Dr. Y. Reiss, Tel Aviv University, Israel). The GM1-binding properties of EtxB and EtxB-conjugates were assessed in a GM1-sandwich ELISA, essentially as previously described (15).

Cell lines and culture conditions

JAWSII, an immortalised C57BL/6 bone marrow-derived dendritic cell line (U.S. patent 5,648,219), was purchased from the American Type Culture Collection (Manassas), and cultured in RP10 medium (RPMI 1640 containing Glutamax-I, 100 µg/ml penicillin/streptomycin and 10% foetal bovine serum (FBS)(all from GIBCO BRL, Paisley, UK)) supplemented with 2 ng/ml recombinant mouse GM-CSF (Sigma) at 37°C in a humidified CO₂ incubator. T-cell hybridoma RF33.70 (16), recognising the OVA(257-264) SIINFEKL peptide in the context of H-2 K^b MHC-I, was a kind gift from Dr. K.L. Rock (University of Massachusetts), and was cultured as above in RP10 medium containing 20 mM HEPES, 1 mM non-essential amino acids, 25 µM indomethacin, 0.25 µg/ml fungizone one (all from GIBCO), and 5 × 10⁻⁵ M 2-ME.

Antigen presentation assays

Peptide presentation by MHC-I was examined by monitoring IL-2 release by the RF33.70 T-cell hybridoma (16). JAWSII dendritic cells were seeded in 96-well plates at 2×10^5 cells/ml and cultured overnight. Cells were then incubated with duplicate test samples at the concentrations and for the time intervals indicated. In all experiments equivalent amounts of either free or conjugated peptide were used. After incubation with antigen cells were fixed with 1% paraformaldehyde for 10 min at room temperature, washed 5x with medium, and incubated overnight with RF33.70 T-cell hybridoma (5×10^5 cells/ml). Free 8mer SIINFEKL peptide and PBS were used as positive and negative controls, respectively. After overnight incubation, presentation-induced IL-2 secretion was determined using a commercially available IL-2 ELISA kit (Pharmingen, San Diego). IL-2 levels are given as mean U/ml \pm standard deviation (SD). Presented data are representative of at least 3 independent experiments.

15

An alternative FACS-based method for a direct assessment of antigen presentation by JAWSII cells, involving the use of the 25D1.16 mAb directed against the MHC-I/SIINFEKL complex (17) (kindly donated by Drs C. Reis e Sousa, Imperial Cancer Research Fund, UK) was also used to assess EtxB-mediated class I presentation. In brief, $2-4 \times 10^6$ JAWSII cells were treated with peptide or EtxB alone or admixed, or EtxB-conjugate at the equivalent concentration of 100 nM peptide for 2 h in a 25 cm^2 tissue culture flask. Cells were then trypsinised, centrifuged (5 min, 1000 rpm), washed with PBS/FBS/azide (PBS containing 5% FBS, and 0.02% sodium azide), and incubated with 25D1.16 mAb (1:200), 30 min, 4°C. Subsequently, cells were washed with PBS/azide, and incubated with a FITC-labelled goat antibody specific for mouse IgG (1:500)(DAKO, Cambs, UK), 30 min, 4°C. Finally, cells were washed with FACS flow (Becton Dickinson, San Jose), and analysed by flow cytometry (FACScan; Becton Dickinson). SIINFEKL peptide-treated and untreated cells were used as controls.

25

The inhibitory effects of Bafilomycin A1 (BafA1), Brefeldin A (BFA)(both from Sigma), and epoxomicin (Calbiochem, Nottingham, UK) on EtxB-mediated delivery were also studied. In such experiments, JAWSII cells were pre-incubated with

30

inhibitors for 1 h at indicated concentrations. Subsequently, cells were incubated with EtxB-conjugates or EtxB and peptide alone or admixed for 2 h and processed as above.

5 *Confocal microscopy*

For microscopic analysis JAWSII cells were first grown for 48 h on sterile cover slips coated with rat collagen type II (Sigma). Subsequently, cells were treated for indicated periods of time with EtxB-conjugates, fixed with 4% paraformaldehyde for 10 min, and then permeabilised by a 15 min incubation in 4% paraformaldehyde containing 0.5% Triton X-100 (Sigma). After repeated washing with PBS, cells were 10 incubated with either mAb 25D1.16, specific for the MHC-I/SIINFEKL complex (1:200), or an EtxB-specific polyclonal rabbit anti-serum (1:500)(kindly provided by Dr. M. Pizza) diluted in PBS/BSA (PBS containing 3% bovine serum albumin (fraction V, Sigma)) for 1 h at room temperature. Cells were then washed with PBS, 15 and incubated with FITC- or TRITC-labelled secondary antibodies directed against mouse or rabbit IgG (1:100)(Jackson Immuno Research Laboratories, West Grove). In some experiments, fixed cells were pre-treated with rhodamine-labelled wheat germ agglutinin (WGA, Sigma) to visualise plasma and Golgi membranes. Washed cover slips were then mounted onto glass examination slides spotted with Mowiol 20 containing 2.5% 1,4-diazabicyclo[2.2.2]octane (DABCO) anti-fading and 4',6-diamidino-2-phenylindole dihydrochloride (DAPI)(1 mg/ml) for nuclear staining (all from Sigma), and then examined using a Leica DH1RBE inverted confocal microscope (Leica, Buffalo) at the MRC Cell Imaging Facility of the Department of Biochemistry, University Bristol.

25

Example 6

Epitope attachment to EtxB

Based on our previous finding that the fusion to EtxB of a 27 amino acid, C-terminal 30 peptide from the DNA polymerase (Pol) of HSV-1 enabled the peptide to be delivered into eukaryotic cells (14), it was decided to assess if the B-subunit could be used as a generic vehicle for delivery of epitopes into the class I presentation pathway. Since the Pol-peptide contained a number of features speculated to be involved in peptide

liberation and endosomal translocation, namely a putative cathepsin D cleavage site (EKL↓AG↓F) and a loop segment of hydrophobic and charged amino acids (AGFGAVGAGATAEE), these elements were incorporated adjacent to the well-characterised class I epitope (SIINFEKL) of ovalbumin. Thus, a 26-mer synthetic peptide was designed containing an N-terminal cysteine residue suitable for chemical conjugation, and the putative cleavage site, Pol-loop segment segment and model class I epitope (Table 1), and then chemically conjugated to EtxB as described in Materials & Methods.

10 **Results 6**

The resultant conjugate retained the characteristic stability properties of EtxB, migrating as a pentameric high molecular weight species on SDS-polyacrylamide gels if kept unheated prior to analysis, and dissociating into monomers when boiled (Fig. 15 6A, lanes 3 and 4). The unheated conjugate had an electrophoretic mobility that was slower and had a more diffuse appearance than the native EtxB pentamer, suggestive of attachment of several 26-mer peptides per EtxB molecule (compare lanes 1 and 3). Upon boiling, monomeric conjugate species with one, two, or more conjugated peptides per EtxB monomer were evident (lane 4). Western blot analysis of EtxB and 20 EtxB-26mer conjugate demonstrated recognition of pentameric EtxB and EtxB-26mer conjugate by a mAb 118-8, specific for the EtxB pentamer (Fig 6B), and recognition of pentameric and monomeric EtxB-26mer by a SIINFEKL-specific polyclonal antiserum (Fig. 6C). In GM1-binding ELISAs, the EtxB-26mer conjugate could readily be detected with both EtxB- and SIINFEKL-specific antibodies, confirming its 25 capacity to bind to GM1 (Fig. 6D and E). The conjugate peptide:EtxB pentamer ratio, estimated by gel filtration chromatography, together with the conjugate concentration, was used to determine the apparent concentration of peptide in the conjugate as described in Materials & Methods.

Example 7**EtxB-26mer conjugate efficiently delivers SIINFEKL peptide into the class I presentation pathway**

5

The capacity of the EtxB-26mer conjugate to deliver the OVA-derived SIINFEKL epitope into MHC-I was investigated in antigen presentation assays using JAWSII cells as antigen-presenting cells, and IL-2 release by the SIINFEKL-specific RF33.70 T-cell hybridoma as a read-out for antigen presentation.

10

Results 7

Fig. 7A shows that the EtxB-26mer conjugate, but not peptide alone or EtxB admixed with peptide stimulated class I-restricted antigen presentation in a dose-dependent fashion. EtxB-mediated delivery reached plateau levels at the equivalent of 100 nM peptide, and IL-2 levels were comparable to those observed if cells were incubated with a free 8-mer SIINFEKL peptide (Fig. 7A). For a more direct assessment of antigen presentation, a FACS-based assay involving the use of mAb 25D1.16 specific for MHC-I/SIINFEKL complexes, was employed. The results obtained were in complete agreement with the IL-2 release data. Accordingly, the EtxB-26mer conjugate and free SIINFEKL peptide induced a clear and similar shift in fluorescence (Fig. 7B), while EtxB and 26mer peptide alone or admixed failed to induce a shift in fluorescence (data not shown). This enhancement of antigen presentation was not due to EtxB-induced upregulation of MHC-I expression, as MHC-I expression levels remained unchanged after treatment with EtxB conjugates (data not shown). Thus, the observed IL-2 release was the result of the appearance of MHC-I/SIINFEKL complexes on the cell surface and subsequent recognition and IL-2 production by the RF33.70 T cell hybridoma.

30

Example 8**Inclusion of elements of the Pol peptide increase the efficiency of EtxB-mediated class I delivery**

5 In an attempt to confirm whether structural elements within the 26mer peptide were responsible for facilitating peptide delivery, 4 additional peptides, namely a 9mer, 16mer, 19mer and 26mer* were designed to address the contribution of the putative cleavage region and the Pol-loop segment (Table 1). All peptides were conjugated to EtxB and their ability to bind to GM1 was confirmed by GM1-sandwich ELISA as
10 above (data not shown).

Results 8

Fig. 8A shows that all of the EtxB-peptide conjugates, when used at 100 nM peptide equivalents, were able to trigger antigen presentation. Like the 8mer, the 9mer CSIINFEKL peptide, significantly stimulated class I presentation when tested alone or when admixed with EtxB, indicating that it is capable of loading directly onto MHC-I molecules present on the cell surface. Interestingly, the extent of peptide delivery when the EtxB-9mer was used was lower than for that achieved with the free 9mer
15 peptide (Fig. 8A). The larger peptides could not load directly onto MHC-I, and were dependent on EtxB-mediated delivery for their presentation. The extent of EtxB-mediated delivery of the 16-mer peptide, that contains the putative cleavage region adjacent to the SIINFEKL epitope, was very similar to that of the EtxB-9mer conjugate. This indicates that the inclusion of the putative cathepsin D cleavage site
20 does not contribute significantly to the extent of epitope delivery. By contrast, conjugation to EtxB of the 19mer and 26mer peptides, which both contain the Pol-loop segment, resulted in increased peptide delivery, comparable to the maximal loading achieved with free 8mer SIINFEKL peptide (Fig. 8A). We therefore conclude
25 that incorporation of the Pol-loop segment adjacent to the class I epitope causes a marked increase in the extent of EtxB-mediated epitope presentation.

To assess the kinetics of appearance of MHC-I/SIINFEKL complexes on the cell surface, cells were fixed at various time points after incubation with the EtxB conjugates. After 5 min incubation with the conjugates no peptide presentation was

evident, whilst after 15 min maximal presentation levels had been attained by all of the conjugates (Fig 8B). As expected, addition of the free 8mer SIINFEKL peptide, resulted in peptide presentation at the earliest time point tested.

5 To further investigate if the intrinsic properties of the Pol-loop segment contribute to peptide delivery, a 26mer* peptide was designed (Table 1). This contained a single Val to Arg substitution that should disrupt the relative hydrophobicity of the Pol-loop segment. When tested, the EtxB-26mer* conjugate exhibited a marked alteration in kinetics of SIINFEKL epitope delivery with no presentation evident within the first 10 min, and only reaching maximal presentation after 120 min (Fig. 8B). Therefore, 10 inclusion of the native Pol-loop segment appears to contribute to the efficiency of EtxB-mediated epitope delivery into the MHC-I presentation pathway.

Example 9(a)

15 **Endosomal acidification and an intact Golgi are required for EtxB-mediated epitope delivery**

The trafficking pathway by which EtxB mediates the delivery of conjugated peptides into the MHC-I pathway was investigated using Bafilomycin A1 (BafA1), an inhibitor 20 of the V-ATPase responsible for acidification of organelles of the endocytic pathway (18) and Brefeldin A (BFA), a Golgi-disrupting drug and inhibitor of vesicle-mediated secretion (19).

Results 9(a)

25 Treatment of JAWSII cells for 60 min with BafA1 or BFA, prior to addition of the EtxB-9mer, -16mer, -19mer, -26mer, and -26mer* conjugates, led to complete inhibition of EtxB-mediated epitope delivery, as assessed using both the IL-2 release assay and FACS detection of MHC-I/SIINFEKL complexes. Since the results 30 obtained with all of the above conjugates were identical, only the data using the EtxB-19mer are shown (Fig 9B-C & F-G). Importantly, treatment of JAWSII cells with BafA1 or BFA did not inhibit the direct loading and presentation of the free 8mer peptide (Fig. 9B-C). Also, when monensin, a Na⁺-ionophor inhibitor of endosomal acidification was tested, EtxB-mediated epitope delivery was prevented, while

presentation of the free 8mer peptide was unaffected (data not shown). Taken together these findings suggest that EtxB-mediated peptide presentation depends upon conjugate entry into acidic endosomes and targeting to the Golgi network.

5 **Example 9(b)**

Proteasome involvement in EtxB-mediated epitope presentation

To assess the possible requirement for proteasome-mediated processing of peptides delivered by EtxB, the effect of well-characterised proteasome inhibitors was tested.

10

Results 9(b)

When epoxomicin, a specific proteasome inhibitor (20), was added to JAWSII cells 60 min prior to the addition of either EtxB-19mer or free 8mer, no inhibition of 15 epitope presentation was observed (Fig. 9D & H). Likewise, lactacysin and MG132, two additional inhibitors of proteasome activity, failed to prevent EtxB-mediated or free epitope presentation (data not shown). Similar results were obtained when all of the other EtxB peptide conjugates were tested in the presence of epoxomicin, lactacysin or MG132 (data not shown). While such results are suggestive of a lack of 20 proteasome involvement in the pathway of EtxB-mediated epitope delivery and presentation, Rock and colleagues have shown that proteasome cleavage of ovalbumin creates the proper C-terminus of the SIINFEKL epitope, whereas distinct peptidases in the cytosol or ER generate the appropriate N-terminus from extended peptides (21,22). Consequently, since all of the peptides we had tested contained the 25 SIINFEKL epitope at their C-terminus, it is highly unlikely that the pathway of delivery of these epitopes would depend on proteasome-mediated cleavage. Therefore, in order to directly investigate if the proteasome could be a participant, a further 31mer peptide was designed, comprising a five amino acid extension on the 30 26mer, thus creating an internal SIINFEKL epitope (Table 1). Incubation of JAWSII cells with the EtxB-31mer resulted in the efficient presentation of the SIINFEKL epitope, as assessed by the IL-2 release assay and by FACS (Fig. 9A & E). As above, prior treatment with BafA1 or BFA prevented EtxB-31mer mediated epitope presentation (Fig. 9B-C & F-G). However, in contrast to the behaviour of the other conjugates, epitope delivery by the EtxB-31mer was completely blocked by the

addition of epoxomicin (Fig. 9D & H), lactacystin and MG132 (data not shown). This demonstrates that proteasome-mediated cleavage of the 31mer peptide is necessary for it to enter the class I presentation pathway.

5 **Example 10**

EtxB-conjugates traffic to the Golgi where newly synthesised MHC-I molecules are loaded

To visualise the trafficking pathway of the EtxB conjugates and to determine the
10 localisation of MHC-I complexes, cells were treated with EtxB-19mer or EtxB-
31mer, and stained with antibodies directed against EtxB or MHC-I/SIINFEKL and
then examined by confocal microscopy.

Results 10

15 After 1 min of incubation with the conjugates, the EtxB moiety could be clearly seen at the cell surface while MHC-I/SIINFEKL complexes were undetectable (Fig. 10A, images e-h). After 120 min, both EtxB-19mer and -31mer were almost completely internalised and perinuclear staining was evident with both EtxB- and MHC-
20 I/SIINFEKL-specific antibodies, with considerable co-localisation (Fig. 10A, images i-l).

This perinuclear staining was suggestive of localisation of both EtxB and the MHC-I/SIINFEKL complexes in the ER or Golgi network, consistent with both the
25 trafficking pathway of EtxB (23) and the normal cellular location of newly synthesised MHC-I molecules (6). In order to identify the cellular localisation of the MHC-I/SIINFEKL complexes more accurately, fixed cells were treated with rhodamine-labelled wheat germ agglutinin (WGA), specific for N-acetyl- β -D-acetylglucosamine present in Golgi/ER and plasma membranes (24), followed by anti-MHC-I/SIINFEKL and secondary antibodies (Fig. 10B). It was found that WGA and MHC-I/SIINFEKL complexes co-localised, confirming that these complexes were present in the Golgi (Fig 10B, images a-d). Moreover, when cells were pre-incubated with epoxomicin to inhibit proteasome acitivity, no staining with MHC-I/SIINFEKL-

specific antibodies was obtained when cells were treated with EtxB-31mer (Fig. 10B, images d vs h), whereas normal co-localisation of WGA and MHC-I/SIINFEKL complexes was observed when cells were treated with EtxB-19mer (Fig. 10B, images c vs g). In addition, no detectable MHC-I/SIINFEKL complexes were observed when 5 cells were treated with BafA1 or BFA, prior to addition of the EtxB-19mer or EtxB-31mer conjugates (data not shown). The above findings on the effects of the trafficking and proteasome inhibitors are in full agreement with the results obtained in the antigen presentation assays. We therefore conclude, that EtxB is an effective delivery vehicle capable of targeting attached epitopes from an exogenous location 10 into the endogenous, proteasome-dependent, class I antigen processing and presentation pathway.

Example 11 (a)

15 ***EtxB mutants retain their targeting potential even though they has lost their immunomodulatory properties***

Fig11 shows a time course of entry of the EtxB(H57S) mutant into Jurkat T-cells in comparison with the wild-type B-subunit.

20

Results 11 (a)

EtxB(H57S), like CtxB(H57A) described in Examples 1-5 above retains binding to GM1, but lacks the ability to trigger signalling events in leukocytes. As Figure 11 25 shows, both wild-type EtxB and the mutant traffic into Jurkat T-cells with similar kinetics and cellular distribution. This the data that indicates that the mutants will retain their drug targeting potential even though they have lost their potent immunomodulatory properties

30

SUMMARY***Part I (Examples 1-5 mutants - GM-1 binding and no immunomodulation)***

5 To investigate whether this region of the B-subunits is important for toxin action in disease and in B-subunit-mediated immunomodulation, the individual residues of the loop were sequentially substituted for Ala. Here we show that one of the mutants, with a His to Ala substitution at position 57 (CtxB(H57A)) is severely defective as an immunomodulator, and that the corresponding holotoxin, Ctx(H57A) exhibits ablated toxicity even though these molecules retain the ability to bind with high affinity to 10 GM1. X-ray crystallographic analysis of CtxB(H57A) revealed that the loop region had undergone a striking 7 Å shift, partially occluding the pore region on the lower convoluted surface of the molecule, whilst not altering the capacity of the receptor pocket to co-crystallize with galactose. This indicates that the loop defines an 15 important site on cholera toxin that is essential for its diverse activities, and that GM1-binding alone is not sufficient to trigger toxin action.

Part II Example 6-11 (Use of wild type/mutant EtxB to deliver exogenous peptides into the class I antigen processing and presentation pathways)

20 Here, we demonstrate that when a class I epitope is attached to EtxB, it can be delivered into the class I presentation pathway. Furthermore, we show that the efficiency of EtxB-mediated peptide delivery can be augmented by incorporating a 10 amino acid segment of the Pol-peptide adjacent to the class I epitope. Addition of a C-terminal extension to such epitope constructs led to class I presentation being 25 completely dependent on proteasome activity. These findings, together with observations that presentation was dependent on endosomal acidification and an intact Golgi compartment, would indicate that EtxB acts as a trafficking molecule that facilitates delivery of exogenous epitopes into the endogenous pathway of class I 30 antigen processing and presentation.

DISCUSSION (Part I)

GM1-ganglioside receptor-binding by the B-subunit of cholera toxin (CtxB) is widely accepted to initiate toxin action, by triggering uptake and delivery of the toxin A-subunit into cells. More recently, GM1-binding by isolated CtxB, or the related B-subunit of *E. coli* heat-labile enterotoxin (EtxB) has been found modulate leukocyte function, resulting in the down-regulation of proinflammatory immune responses that cause autoimmune disorders such as rheumatoid arthritis and diabetes.

10 The present invention demonstrates that GM1-binding, contrary to expectation, is not sufficient to initiate the potent toxic or immunomodulatory action of the toxin. Data from studies carried out on engineering and crystallographic structure of a mutant cholera toxin, with a His to Ala substitution in the B-subunit at position 57 demonstrated that the mutant retained pentameric stability and high affinity binding to
15 GM1-ganglioside, but lost its immunomodulatory activity and, when part of the holotoxin complex, exhibited ablated toxicity.

Why does an H57A mutation in CtxB attenuate Ctx action and ablate B-subunit-mediated immunomodulation?

20 It is possible that the H57A mutation subtly alters the nature of interaction with GM1 so that putative, and as yet ill-defined down-stream events cannot be activated. Previous crystallographic studies have revealed that the only structural change that occurs when B-pentamers interact with the pentasaccharide of GM1, or with other
25 carbohydrates such as galactose, is that the loop region becomes more rigid (4). Whilst the significance of this has not been explored, it is possible that the transition from a flexible to a rigid structure contributes to the way in which bound GM1-moieties are tethered in the membrane. In this regard, the X-ray crystallography revealed that the loop of the H57A mutant receptor pocket, lacking bound
30 carbohydrate, appeared to have already adopted a more rigid structure. This would therefore preclude the possibility of such a structural transition contributing to GM1-crosslinking in ways that may result in activation of down-stream events.

Alternatively, cholera toxin may require interaction, not only with GM1, but also with another cell surface molecule for it to exert its biological activity. It is conceivable that after binding to GM1, the loops in the B-pentamer are positioned to directly interact with other membrane components, possibly a transmembrane protein.

5 Consequently, the alteration in the position of the loops in the B-subunit mutants may prevent this from happening, even though the molecule is tethered to the membrane via GM1. Importantly, GM1 is preferentially located in cholesterol-rich detergent-insoluble membrane microdomains, termed 'rafts', which contain numerous proteins involved in cell signalling (17). us, it is conceivable that wild type CtxB binding to

10 GM1 in rafts positions it to interact with signalling molecules at the membrane surface that participate in toxin-mediated trafficking and immune cell modulation.

The data from the present invention provides evidence that the H57 mutation does not interfere with uptake or trafficking in a variety of cell types suggesting that the

15 mutants are defective in signal transduction.

Discussion Part II (Example 6-11)

Utility of using wild-type EtxB as vehicle to deliver class I epitopes

20 Cytotoxic CD8+ T lymphocytes (CTL) represent an important component of the protective and therapeutic immune response to viral infections and tumours via their capacity to recognise foreign peptides that have bound to major histocompatibility complex class I (MHC-I) molecules (1,2). The majority of the peptides presented are derived from endogenously synthesised or cytoplasmically localised proteins that are

25 cleaved into small peptide fragments by the proteasome (3,4). These are then transported via the transporter of antigenic peptides (TAP) into the lumen of the endoplasmatic reticulum (ER), where they bind to newly synthesised MHC-I molecules (5,6). Such MHC-I peptide complexes are trafficked to the cell surface whereupon they are recognised by T-cell receptors present on CTLs. This leads to

30 CTL activation and subsequent CTL-mediated lysis of the peptide-presenting cell (1,2).

Given the importance of CTLs in clearing the host of infected cells, there is a great interest in the development of new vaccination strategies that are capable of inducing

effective CTL responses. However, for vaccines composed of soluble protein antigens, immunisation results in antigen uptake into an exogenous processing pathway that leads to peptide fragments being loaded onto MHC class II molecules (MHC-II), rather than MHC-I (7). Thus in order for soluble antigens to induce MHC-I restricted CTL responses, antigens need to access intracellular compartments where they can enter the endogenous class I processing and presentation pathway (7).

Bacterial protein toxins are molecules that combine unique cell-binding with efficient cytosolic delivery properties (8). They would therefore appear to be ideally suited for the delivery of antigenic proteins and peptides in the class I presentation pathway, provided that detoxification without apparent loss of delivery capability can be achieved. Indeed, toxoid derivatives of adenylate cyclase toxin of *Bordetella pertussis* (9), pertussis toxin (10), anthrax toxin (11,12), and Shiga toxin B subunit (13) have been investigated as potential vehicles for delivery of peptides or proteins into the class I presentation pathway. The non-toxic GM1-binding B-subunit of the *Escherichia coli* heat-labile enterotoxin (EtxB) has recently also been shown to be a suitable vehicle for the delivery of peptides into specific intracellular compartments (14). In particular, when a 27-mer peptide derived from the C-terminus of the DNA polymerase (Pol) of herpes simplex virus type 1 (HSV-1) was genetically fused to the C-terminus of EtxB, it was found that the fusion protein entered cells, and that the peptide was liberated from EtxB and translocated into the nuclear compartment. While structural features present in the Pol-peptide were speculated to be involved in facilitating both its liberation from EtxB and translocation from endosomal compartments, their contribution to peptide delivery remained undefined. Here we have investigated: (i) whether EtxB can be used as a vehicle for the delivery of exogenous peptides into the class I presentation pathway and (ii) whether incorporation of elements of the Pol-peptide adjacent to the class I epitope would improve the efficiency of peptide delivery.

We have shown that EtxB is an effective vehicle for delivery of an epitope into the MHC-I pathway. The capacity of EtxB to bind to cells is essential for epitope delivery, since conjugates comprising peptides linked to a non-binding mutant of EtxB, EtxB(G33D) (25), failed to trigger peptide presentation. Given the finding that the proteasome can participate in the pathway of EtxB-mediated epitope presentation,

it would imply that conjugated peptides are liberated from EtxB and translocated into the cytosol for proteasome processing.

Intrinsic properties of conjugated peptides were found to contribute to the extent and efficiency of epitope presentation. In this respect, conjugated peptides that were capable of achieving levels of presentation comparable to direct loading by the free SIINFEKL peptide, all contained the Pol-loop segment, exemplified by the EtxB-19mer conjugate. This segment was derived from a domain within the C-terminal region of HSV-1 polymerase and is part of a 36 amino acid hairpin-like structure, consisting of two helical regions interrupted by a flexible loop region that contains two glutamate residues (26,27). The Pol segment used in the current study contains the two glutamates and the flexible region composed of hydrophobic and nonpolar amino acids, and it shows a degree of similarity with fusion peptides from viral glycoproteins (28). Therefore, one explanation for the improved delivery of the SIINFEKL epitope by peptides containing the Pol-loop segment, may be that this segment has an intrinsic propensity to penetrate lipid bilayers. Furthermore, it is known that for pH-dependent translocation, protonation of acidic residues in helical hairpins permits insertion of hydrophobic domains into lipid bilayers (29). Thus, liberation from EtxB, followed by protonation of the glutamates and then translocation across a vesicular membrane into the cytosol should permit highly efficient entry into the endogenous class I presentation pathway.

In support of this hypothesis, the mutated 26mer peptide, 26mer*, with an Arg substitution in the middle of the Pol-loop segment, displayed slower delivery kinetics, possibly due to decreased translocation efficiency. Moreover, the finding that BafA1 and monensin inhibited EtxB-mediated epitope presentation indicates that entry into an acidic endosome is essential for peptide delivery. Given that the trafficking and toxicity of cholera toxin is refractory to chaotropic agents (30), this would imply that entry into an acidic environment is required for efficient epitope delivery rather than for trafficking of the carrier. Consequently, an acidic environment could enable protonation of the Pol-loop glutamate residues for subsequent translocation. It is also possible that entry into acidic endosomes is necessary for peptide liberation from EtxB as a result of the activity of acid-dependent proteases such as cathepsins. However, when EtxB-mediated presentation of the 26mer peptide was assessed in the

presence of pepstatin, an inhibitor of acid proteases, it had no effect on the extent of SIINFEKL presentation. In addition, there was no difference in the extent of epitope presentation mediated by EtxB-19mer and EtxB-26mer conjugates, the former of which lacks the putative cathepsin D cleavage sites. Inhibitors of metallo-aminopeptidases and serine and cysteine proteases, bestatin and leupeptin, also had no significant effects on EtxB-mediated epitope presentation. The metallo-protease inhibitor 1,10-phenanthroline was, however, found to inhibit EtxB-induced antigen presentation, suggesting that a metallo-protease may be involved in either liberation and/or processing of the EtxB conjugated peptides.

10

The ability of EtxB and the Pol-loop segment to efficiently deliver class I restricted epitopes into the endogenous MHC-I pathway should open up new opportunities for design of vaccines able to stimulate protective cytotoxic T-cell responses. Given that the efficiency of CTL-mediated killing is directly related to the number of specific MHC-I peptide complexes on the cell surface (31), it is encouraging that the extent of peptide delivery mediated by EtxB reached comparable levels to direct loading of peptides onto surface MHC-I molecules.

20

All publications mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described methods and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

25

REFERENCES (Part I)

1. Hirst, T. R. (1999) in *The Comprehensive Sourcebook of Bacterial Protein Toxins*, ed. Freer, J. E. A. a. J. H. (Academic Press, London), pp. 104-129.
- 5 2. Lencer, W. I., Hirst, T. R. & Holmes, R. K. (1999) *Biochim. Biophys. Acta* 1450, 177-190.
3. Holmgren, J., Lönnroth, I. & Svennerholm, L. (1973) *Infect. Immun.* 8, 208-214.
4. Sixma, T. K., Kalk, K. H., van Zanten, B. A. M., Dauter, Z., Kingma, J., Witholt, B. & Hol, W. G. J. (1993) *J. Mol. Biol.* 230, 890-918.
- 10 5. Williams, N. A., Hirst, T. R. & Nashar, T. O. (1999) *Immunol. Today* 20, 95-101.
6. Verweij, W. R., de Haan, L., Holtrop, M., Agsteribbe, E., Brands, R., van Scharrenburg, G. J. M. & Wilschut, J. (1998) *Vaccine* 16, 2069-2076.
- 15 7. Richards, C. M., Aman, A. T., Hirst, T. R., Hill, T. J. & Williams, N. A. (2001) *Journal of Virology* 75, 1664-1671.
8. Sun, J. B., Rask, C., Olsson, T., Holmgren, J. & Cerkinsky, C. (1996) *Proc. Natl. Acad. Sci. (USA)* 93, 7196-7201.
9. Williams, N. A., Stasiuk, L. M., Nashar, T. O., Richards, C. M., Lang, A. K., Day, M. J. & Hirst, T. R. (1997) *Proc. Natl. Acad. Sci. (USA)* 94, 5290-5295.
- 20 10. Bergerot, I., Ploix, C., Petersen, J., Moulin, V., Rask, C., Fabien, N., Lindblad, M., Mayer, A., Cerkinsky, C., Holmgren, J. & Thivolet, C. (1997) *Proc. Natl. Acad. Sci. (USA)* 94, 4610-4614.
11. Francis, M. L., Ryan, J., Jobling, M. G., Holmes, R. K., Moss, J. & Mond, J. J. (1992) *J. Immunol.* 148, 1999-2005.
- 25 12. Nashar, T. O., Hirst, T. R. & Williams, N. A. (1997) *Immunology* 91, 572-578.
13. Nashar, T. O., Webb, H. M., Eaglestone, S., Williams, N. A. & Hirst, T. R. (1996) *Proc. Natl. Acad. Sci. (USA)* 93, 226-230.
14. Nashar, T. O., Williams, N. A. & Hirst, T. R. (1996) *Int. Immunol.* 8, 731-736.
- 30 15. Wolf, A. A., Jobling, M. G., Wimer-Mackin, S., Ferguson-Maltzman, M., Madara, J. L., Holmes, R. K. & Lencer, W. I. (1998) *J. Cell Biol.* 141, 917-927.
16. Orlandi, P. A. & Fishman, P. H. (1998) *J. Cell Biol.* 141, 905-915.
17. Parton, R. G., Joggerst, B. & Simons, K. (1994) *J. Cell Biol.* 127, 1199-1215.

18. Merritt, E. A., Sarfaty, S., van den Akker, F., Lhoir, C., Martial, J. A. & Hol, W. G. J. (1994) *Protein Sci.* 3, 166-175.

19. Merritt, E. A., Sixma, T. K., Kalk, K. H., Van Zanten, B. A. M. & Hol, W. G. J. (1994) *Mol. Microbiol.* 13, 745-753.

5 20. Higuchi, R., Krummel, B. & Saiki, R. K. (1988) *Nucleic Acids Res.* 16, 7351-7367.

21. Rodighiero, C., Aman, A. T., Kenny, M. J., Moss, J., Lencer, W. I. & Hirst, T. R. (1999) *J. Biol. Chem.* 274, 3962-3969.

10 22. Furste, J. P., Pansegrouw, W., Frank, R., Blocker, H., Scholz, P., Bagdasarian, M. & Lanka, E. (1986) *Gene* 48, 119-131.

23. Hirst, T. R., Randall, L. L. & Hardy, S. J. S. (1984) *Journal of Bacteriology* 157, 637-642.

24. Ruddock, L. W., Ruston, S. P., Kelly, S. M., Price, N. C., Freedman, R. B. & Hirst, T. R. (1995) *J. Biol. Chem.* 270, 29953-29958.

15 25. Merritt, E. A., Kuhn, P., Sarfaty, S., Erbe, J. L., Holmes, R. K. & Ho, W. G. J. (1998) *J. Mol. Biol.* 282, 1043-1059.

26. Otwinowski, Z. & Minor, W. (1997) *Meth. Enzymol.* 276, 307-326.

27. Bailey, S. (1994) *Acta Crystallogr. Sect. D-Biol. Crystallogr.* 50, 760-763.

28. McRee, D. (1993) *Practical Protein Crystallography* (Academic Press, San Diego).

20 29. Sanner, M. F., Olson, A. J. & Spehner, J. C. (1996) *Biopolymers* 38, 305-320.

30. 30. Merritt, E. A. & Bacon, D. J. (1997) *Meth. Enzymol.* 277, 505-524.

31. Lencer, W. I., Delp, C., Neutra, M. R. & Madara, J. L. (1992) *J. Cell Biol.* 117, 1197-1209.

25 32. Hardy, S. J. S., Holmgren, J., Johansson, S., Sanchez, J. & Hirst, T. R. (1988) *Proc. Natl. Acad. Sci. (USA)* 85, 7109-7113.

33. Sandkvist, M., Hirst, T. R. & Bagdasarian, M. (1990) *J. Biol. Chem.* 265, 15239-15244.

34. Kuziemko, G. M., Stroh, M. & Stevens, R. C. (1996) *Biochemistry* 35, 6375-6384.

30 35. Badizadegan, K., Wolf, A., Rodighiero, C., Jobling, M. G., Hirst, T. R., Holmes, R. K. & Lencer, W. I. (2000) *Int. J. Med. Microbiol.* 290, 403-408.

REFERENCES (PART II)

1. Townsend, A. & Bodmer, H. (1989) *Annu. Rev. Immunol.* **7**, 601-624.
2. Long, E. O. & Jacobsen, S. (1989) *Immunol. Today* **10**, 45-48.
- 5 3. Rock, K. L. & Goldberg, A. L. (1999) *Annu. Rev. Immunol.* **17**, 739-779.
4. Reits, E. A., Vos, J. C., Gromme, M. & Neefjes, J. (2000) *Nature* **404**, 774-778.
5. Hill, A. & Ploegh, H. (1995) *Proc. Natl. Acad. Sci. USA* **92**, 341-343.
6. Heemels, M. T. & Ploegh, H. (1995) *Annu. Rev. Biochem.* **64**, 463-491.
7. Raychaudhuri, S. & Rock, K. L. (1998) *Nat. Biotechnol.* **16**, 1025-1031.
- 10 8. Burnette, W. N. (1994) *Structure* **2**, 151-158.
9. Sebo, P., Fayolle, C., d'Andria, O., Ladant, D., Leclerc, C. & Ullmann, A. (1995) *Infect. Immun.* **63**, 3851-3857.
10. Carbonetti, N. H., Irish, T. J., Chen, C. H., O'Connell, C. B., Hadley, G. A., McNamara, U., Tuskan, R. G. & Lewis, G. K. (1999) *Infect. Immun.* **67**, 602-607.
- 15 11. Ballard, J. D., Collier, R. J. & Starnbach, M. N. (1996) *Proc. Natl. Acad. Sci. USA* **93**, 12531-12534.
12. Goletz, T. J., Klimpel, K. R., Arora, N., Leppla, S. H., Keith, J. M. & Berzofsky, J. A. (1997) *Proc. Natl. Acad. Sci. USA* **94**, 12059-12064.
13. Lee, R. S., Tartour, E., van der Bruggen, P., Vantomme, V., Joyeux, I., Goud, B., Fridman, W. H. & Johannes, L. (1998) *Eur. J. Immunol.* **28**, 2726-2737.
- 20 14. Loregian, A., Papini, E., Satin, B., Marsden, H. S., Hirst, T. R. & Palu, G. (1999) *Proc. Natl. Acad. Sci. USA* **96**, 5221-5226.
15. Amin, T. & Hirst, T. R. (1994) *Prot. Expr. Purif.* **5**, 198-204.
16. Rock, K. L., Rothstein, L. & Gamble, S. (1990) *J. Immunol.* **145**, 804-811.
- 25 17. Porgador, A., Yewdell, J. W., Deng, Y., Bennink, J. W. & Germain, R. N. (1997) *Immunity* **6**, 715-726.
18. Bowman, E. J., Siebers, A. & Altendorf, K. (1988) *Proc. Natl. Acad. Sci. USA* **85**, 7972-7976.
19. Lippincott-Schwartz, J., Yuan, L. C., Bonifacino, J. S. & Klausner, R. D. (1989) *Cell* **56**, 801-813.
- 30 20. Meng, L., Mohan, R., Kwok, B. H., Elofsson, M., Sin, N. & Crews, C. M. (1999) *Proc. Natl. Acad. Sci. USA* **96**, 10403-10408.
21. Craiu, A., Akopian, T., Goldberg, A. & Rock, K. L. (1997) *Proc. Natl. Acad. Sci. USA* **94**, 10850-10855.

22. Cascio, P., Hilton, C., Kisseelev, A. F., Rock, K. L. & Goldberg, A. L. (2001) *EMBO J.* **20**, 2357-2366.

23. Lencer, W. I., Delp, C., Neutra, M. R. & Madara, J. L. (1992) *J. Cell Biol.* **117**, 1197-1209.

5 24. Tartakoff, A. M. & Vassalli, P. (1983) *J. Cell Biol.* **97**, 1243-1248.

25. Nashar, T. O., Webb, H. M., Eaglestone, S., Williams, N. A. & Hirst, T. R. (1996) *Proc. Natl. Acad. Sci. USA* **93**, 226-230.

26. Bridges, K. G., Hua, Q., Brigham-Burke, M. R., Martin, J. D., Hensley, P., Dahl, C. E., Digard, P., Weiss, M. A. & Coen, D. M. (2000) *J. Biol. Chem.* **275**, 472-478.

10 27. Digard, P., Williams, K. P., Hensley, P., Brooks, I. S., Dahl, C. E. & Coen, D. M. (1995) *Proc. Natl. Acad. Sci. USA* **92**, 1456-1460.

28. Samuel, O. & Shai, Y. (2001) *Biochemistry* **40**, 1340-1349.

29. Kaul, P., Silverman, J., Shen, W. H., Blanke, S. R., Huynh, P. D., Finkelstein, A. & Collier, R. J. (1996) *Prot. Sci.* **5**, 687-692.

15 30. Lencer, W. I., Strohmeier, G., Moe, S., Carlson, S. L., Constable, C. T. & Madara, J. L. (1995) *Am. J. Physiol.* **32**, G548-G557.

31. Wherry, E. J., Puorro, K. A., Porgador, A. & Eisenlohr, L. C. (1999) *J. Immunol.* **163**, 3735-3745.

20

25

30

CLAIMS

1. Use of a mutant form of EtxB or CtxB to deliver an agent to a target cell
5 wherein the mutant has GM-1 binding activity; but wherein the mutant has a reduced immunogenic and immunomodulatory activity relative to the wild type form of EtxB or CtxB.
2. Use according to claim 1 wherein the agent is selected from the group
10 consisting of a peptide or protein of interest (POI); an antigen; an antigenic determinant; an antibody; and a nucleotide sequence of interest (NOI).
3. Use according to claim 2 wherein the antigen selected from the group
15 consisting of a viral antigen, a bacterial antigen, a parasitic antigen; and a tumour associated antigen (TAA).
4. Use according to any one of claims 1-3 wherein the agent is delivered into a vesicular compartment of the target cell.
- 20 5. Use according to any one of claims 1- 4 wherein the agent is targeted to the cytosol and/or the nucleus and/or an organelle of the target cell.
6. Use according to any one of the preceding claims wherein the target cell is an antigen presenting cell (APC).
- 25 7. Use according to any one of the preceding claims wherein the mutant comprises a mutation is in the region spanning amino acid residues E51-I58 of the β 4- α 2 loop of CtxB or EtxB.
- 30 8. Use according to claim 7 wherein the mutant comprises a mutation at amino acid residues 51, 56 and/or 57 of the β 4- α 2 loop.

9. Use according to claim 7 or claim 8 wherein the mutant comprises a H57A or H57S mutation.

10. Use of a mutant according to any one of the preceding claims in the preparation of a medicament to deliver an exogenous peptide into the MHC Class I antigen processing and presentation pathways to elicit a CTL response.

11. Use according to claim 10 wherein the exogenous peptide is any one of the agents as defined in claim 3.

12. The use of a mutant as defined in any one of claims 1-11 in the preparation of a medicament for separate, simultaneous or combined use to treat a disease or a condition in a subject in need of same.

13. A method of treating a disease or condition in a subject in need of same wherein the method comprises:

- (i) providing a target cell; and
- (ii) delivering an agent to the target cell using a mutant as defined in any one of claims 1-11.

14. A method according to claim 13 or the use according to any one of claims 10-12 wherein the disease or condition is a viral infection or a cancer.

15. A method of delivering an agent using a mutant to a target cell wherein the method comprises:

- (i) providing a target cell;
- (ii) contacting the cell with the mutant as defined in any one of claims 1-11; and
- (iii) monitoring for the presence of the agent in the target cell.

16. A method according to claim 15 wherein the agent is delivered to a vesicular compartment, and/or cytosol and/or nucleus and/or an organelle of the target cell.

17. A composition, preferably a pharmaceutical composition, comprising a mutant as defined in any one of claims 1-11 and a pharmaceutically acceptable carrier(s), diluent(s), excipient(s) or adjuvant or any combination thereof.

5 18. A kit for delivering an agent to a target cell wherein the kit comprises:

- (i) a mutant as defined in any one of claims 1-11;
- (ii) an agent for delivery to the target cell; and optionally
- (iii) means for detecting the location of the agent in the target cell.

10 19. The use and the method substantially as defined herein and with reference to the accompanying Figures.

15

20

25

30

ABSTRACT**MUTANT**

5

The present invention describes the use of a mutant form of EtxB or CtxB to deliver
an agent to a target cell wherein the mutant has GM-1 binding activity; but wherein
the mutant has a reduced immunogenic and immunomodulatory activity relative to the
10 wild type form of EtxB or CtxB.




Figure 1




Figure 2






Figure 3

A



B



C






Figure 4


Figure 5

A




B







De Haan *et al.*, Figure 6ABCDE




De Haan *et al.*, Figure 7AB



De Haan *et al.*, Figure 8AB



De Haan *et al.*, Figure 9A-H



De Haan *et al.*, Figure 10AB




Figure 11